心肺复苏指南（英文）：Part 12

ISSN: 1524-4539 Copyright ? 2005 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online 72514 Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX DOI: 10.1161/CIRCULATIONAHA.105.166573 2005;112;167-187; originally published online Nov 28, 2005; Circulation Part 12: Pediatric Advanced Life Support http://circ.ahajournals.org/cgi/content/full/112/24_suppl/IV-167 located on the World Wide Web at: The online version of this article, along with updated information and services, is http://www.lww.com/static/html/reprints.html Reprints: Information about reprints can be found online at journalpermissions@lww.com Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email: Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden http://circ.ahajournals.org/subsriptions/ Subscriptions: Information about subscribing to Circulation is online at by on February 21, 2006 circ.ahajournals.orgDownloaded from Part 12: Pediatric Advanced Life Support I n contrast to adults, sudden cardiac arrest in children is uncommon, and cardiac arrest does not usually result from a primary cardiac cause. 1 More often it is the terminal event of progressive respiratory failure or shock, also called an asphyxial arrest. Respiratory Failure Respiratory failure is characterized by inadequate ventilation or oxygenation. Anticipate respiratory failure and possible respiratory arrest if you see any of the following: ● An increased respiratory rate, particularly with signs of distress (eg, increased effort, nasal flaring, retractions, or grunting) ● An inadequate respiratory rate, effort, or chest excursion (eg, diminished breath sounds, gasping, and cyanosis), especially if mental status is depressed Shock Shock results from inadequate blood flow and oxygen deliv- ery to meet tissue metabolic demands. Shock progresses over a continuum of severity, from a compensated to a decompen- sated state. Attempts to compensate include tachycardia and increased systemic vascular resistance (vasoconstriction) in an effort to maintain cardiac output and blood pressure. Although decompensation can occur rapidly, it is usually preceded by a period of inadequate end-organ perfusion. Signs of compensated shock include ● Tachycardia ● Cool extremities ● Prolonged capillary refill (despite warm ambient temperature) ● Weak peripheral pulses compared with central pulses ● Normal blood pressure As compensatory mechanisms fail, signs of inadequate end-organ perfusion develop. In addition to the above, these signs include ● Depressed mental status ● Decreased urine output ● Metabolic acidosis ● Tachypnea ● Weak central pulses Signs of decompensated shock include the signs listed above plus hypotension. In the absence of blood pressure measure- ment, decompensated shock is indicated by the nondetectable distal pulses with weak central pulses in an infant or child with other signs and symptoms consistent with inadequate tissue oxygen delivery. The most common cause of shock is hypovolemia, one form of which is hemorrhagic shock. Distributive and cardio- genic shock are seen less often. Learn to integrate the signs of shock because no single sign confirms the diagnosis. For example: ● Capillary refill time alone is not a good indicator of circulatory volume, but a capillary refill time of H110222 seconds is a useful indicator of moderate dehydration when combined with a decreased urine output, absent tears, dry mucous membranes, and a generally ill appearance (Class IIb; LOE 3 2 ). It is influenced by ambient temperature, 3 lighting, 4 site, and age. ● Tachycardia also results from other causes (eg, pain, anxiety, fever). ● Pulses may be bounding in anaphylactic, neurogenic, and septic shock. In compensated shock, blood pressure remains normal; it is low in decompensated shock. Hypotension is a systolic blood pressure less than the 5th percentile of normal for age, namely: ● H1102160 mm Hg in term neonates (0 to 28 days) ● H1102170 mm Hg in infants (1 month to 12 months) ● H1102170 mm Hg H11001 (2 H11003 age in years) in children 1 to 10 years ● H1102190 mm Hg in children H1135010 years of age Airway Oropharyngeal and Nasopharyngeal Airways Oropharyngeal and nasopharyngeal airways are adjuncts for maintaining an open airway. Oropharyngeal airways are used in unconscious victims (ie, with no gag reflex). Select the correct size: an oropharyngeal airway that is too small will not keep the tongue from obstructing the pharynx; one that is too large may obstruct the airway. Nasopharyngeal airways will be better tolerated than oral airways by patients who are not deeply unconscious. Small nasopharyngeal tubes (for infants) may be easily obstructed by secretions. Laryngeal Mask Airway There is insufficient evidence to recommend for or against the routine use of a laryngeal mask airway (LMA) during cardiac arrest (Class Indeterminate). When endotracheal in- tubation is not possible, the LMA is an acceptable adjunct for experienced providers (Class IIb; LOE 7), 5 but it is associated with a higher incidence of complications in young children. 6 Breathing: Oxygenation and Assisted Ventilation For information about the role of ventilation during CPR, see Part 11: “Pediatric Basic Life Support.” (Circulation. 2005;112:IV-167-IV-187.) ? 2005 American Heart Association. This special supplement to Circulation is freely available at http://www.circulationaha.org DOI: 10.1161/CIRCULATIONAHA.105.166573 IV-167 Oxygen There are no studies comparing various concentrations of oxygen during resuscitation beyond the perinatal period. Use 100% oxygen during resuscitation (Class Indeterminate). Monitor the patient’s oxygen level. When the patient is stable, wean the supplementary oxygen if the oxygen satura- tion is maintained. Pulse Oximetry If the patient has a perfusing rhythm, monitor oxygen saturation continuously with a pulse oximeter because clini- cal recognition of hypoxemia is not reliable. 7 Pulse oximetry, however, may be unreliable in a patient with poor peripheral perfusion. Bag-Mask Ventilation Bag-mask ventilation can be as effective as ventilation through an endotracheal tube for short periods and may be safer. 8–11 In the prehospital setting ventilate and oxygenate infants and children with a bag-mask device, especially if transport time is short (Class IIa; LOE 1 8 ;3 10 ;4 9,11 ). Bag- mask ventilation requires training and periodic retraining on how to select a correct mask size, open the airway, make a tight seal between mask and face, ventilate, and assess effectiveness of ventilation (see Part 11: “Pediatric Basic Life Support”). Precautions Victims of cardiac arrest are frequently overventilated during resuscitation. 12–14 Excessive ventilation increases intratho- racic pressure and impedes venous return, reducing cardiac output, cerebral blood flow, and coronary perfusion. 13 Exces- sive ventilation also causes air trapping and barotrauma in patients with small-airway obstruction and increases the risk of stomach inflation, regurgitation, and aspiration. Minute ventilation is determined by the tidal volume and ventilation rate. Use only the force and tidal volume needed to make the chest rise visibly. During CPR for the patient with no advanced airway (eg, endotracheal tube, esophageal- tracheal combitube [Combitube], LMA) in place, ventilation rate is determined by the compression-ventilation ratio. Pause after 30 compressions (1 rescuer) or after 15 compressions (2 rescuers) to give 2 ventilations with mouth-to-mouth, mouth- to-mask, or bag-mask techniques. Give each breath over 1 second. If an advanced airway is in place during CPR (eg, endo- tracheal tube, Combitube, LMA), ventilate at a rate of 8 to 10 times per minute without pausing chest compressions. In the victim with a perfusing rhythm but absent or inadequate respiratory effort, give 12 to 20 breaths per minute. One way to achieve this rate with a ventilating bag is to use the mnemonic “squeeze-release-release” at a normal speaking rate. 8,15 Two-Person Bag-Mask Ventilation A 2-person technique may be more effective than ventilation by a single rescuer if the patient has significant airway obstruction, poor lung compliance, or difficulty in creating a tight mask-to-face seal. 16,17 One rescuer uses both hands to maintain an open airway with a jaw thrust and a tight mask-to-face seal while the other compresses the ventilation bag. Both rescuers should observe the victim’s chest to ensure chest rise. Gastric Inflation Gastric inflation may interfere with effective ventilation 18 and cause regurgitation. You can minimize gastric inflation by doing the following: ● Avoid excessive peak inspiratory pressures (eg, by venti- lating slowly and watching chest rise). 8 To avoid use of excessive volume, deliver only the volume needed to produce visible chest rise. ● Apply cricoid pressure. You should do so only in an unresponsive victim. This technique may require an addi- tional (third) rescuer if the cricoid pressure cannot be applied by the rescuer who is securing the bag to the face. 19–21 Avoid excessive pressure so as not to obstruct the trachea. 22 ● If you intubate the patient, pass a nasogastric or orogastric tube after you intubate because a gastric tube interferes with the gastroesophageal sphincter, allowing possible regurgitation. Ventilation Through an Endotracheal Tube Endotracheal intubation in infants and children requires special training because the pediatric airway anatomy differs from adult airway anatomy. Success and a low complication rate are related to the length of training, supervised experi- ence in the operating room and in the field, 23,24 adequate ongoing experience, 25 and the use of rapid sequence intuba- tion (RSI). 23,26,27 Rapid Sequence Intubation To facilitate emergency intubation and reduce the incidence of complications, skilled, experienced providers may use sedatives, neuromuscular blocking agents, and other medica- tions to rapidly sedate and paralyze the victim. 28 Use RSI only if you are trained and have experience using these medications and are proficient in the evaluation and manage- ment of the pediatric airway. If you use RSI you must have a secondary plan to manage the airway in the event that you cannot achieve intubation. Cuffed Versus Uncuffed Tubes In the in-hospital setting a cuffed endotracheal tube is as safe as an uncuffed tube for infants beyond the newborn period and in children. 29–31 In certain circumstances (eg, poor lung compliance, high airway resistance, or a large glottic air leak) a cuffed tube may be preferable provided that attention is paid to endotracheal tube size, position, and cuff inflation pressure (Class IIa; LOE 2 30 ;3 29,31 ). Keep cuff inflation pressure H1102120 cm H 2 O. 32 Endotracheal Tube Size The internal diameter of the appropriate endotracheal tube for a child will roughly equal the size of that child’s little finger, but this estimation may be difficult and unreliable. 33,34 Sev- eral formulas such as the ones below allow estimation of proper endotracheal tube size (ID, internal diameter) for children 1 to 10 years of age, based on the child’s age: IV-168 Circulation December 13, 2005 Uncuffed endotracheal tube size (mm ID) H11005(age in years/4) H11001 4 In general, during preparation for intubation using the above formula, providers should have the estimated tube size available, as well as uncuffed endotracheal tubes that have internal diameters that are 0.5 mm smaller and 0.5 mm larger than the size estimated ready at the bedside for use. The formula for estimation of a cuffed endotracheal tube size is as follows 30 : Cuffed endotracheal tube size (mm ID) H11005 (age in years/4) H11001 3 Endotracheal tube size, however, is more reliably based on a child’s body length. Length-based resuscitation tapes are helpful for children up to approximately 35 kg. 35 Verification of Endotracheal Tube Placement There is a high risk that an endotracheal tube will be misplaced (ie, placed in the esophagus or in the pharynx above the vocal chords), displaced, or become obstructed, 8,36 especially when the patient is moved. 37 No single confirma- tion technique, including clinical signs 38 or the presence of water vapor in the tube, 39 is completely reliable, so providers must use both clinical assessment and confirmatory devices to verify proper tube placement immediately after intubation, during transport, and when the patient is moved (ie, from gurney to bed). Immediately after intubation and again after securing the tube, confirm correct tube position with the following tech- niques while you provide positive-pressure ventilation with a bag: ● Look for bilateral chest movement and listen for equal breath sounds over both lung fields, especially over the axillae. ● Listen for gastric insufflation sounds over the stomach (they should not be present if the tube is in the trachea). 38 ● Use a device to evaluate placement. Check for exhaled CO 2 (see below) if there is a perfusing rhythm. If the child has a perfusing rhythm and is H1102220 kg, you may use an esophageal detector device to check for evidence of esoph- ageal placement (see below). ● Check oxygen saturation with a pulse oximeter. Following hyperoxygenation, the oxyhemoglobin saturation detected by pulse oximetry may not demonstrate a fall indicative of incorrect endotracheal tube position (ie, tube misplacement or displacement) for as long as 3 minutes. 40,41 ● If you are still uncertain, perform direct laryngoscopy and look to see if the tube goes between the cords. ● In hospital settings perform a chest x-ray to verify that the tube is not in the right main bronchus and to identify a high tube position at risk of easy displacement. After intubation secure the tube. There is insufficient evidence to recommend any one method (Class Indetermi- nate). After you secure the tube, maintain the patient’s head in a neutral position; neck flexion pushes the tube farther into the airway, and extension pulls the tube out of the airway. 42,43 If an intubated patient’s condition deteriorates, consider the following possibilities (DOPE): ● Displacement of the tube from the trachea ● Obstruction of the tube ● Pneumothorax ● Equipment failure Exhaled or End-Tidal CO 2 Monitoring In infants and children with a perfusing rhythm, use a colorimetric detector or capnography to detect exhaled CO 2 to confirm endotracheal tube position in the prehospital and in-hospital settings (Class IIa; LOE 5 44 ) and during intrahos- pital and interhospital transport (Class IIb; LOE 5 45 ). A color change or the presence of a capnography waveform confirms tube position in the trachea but does not rule out right main bronchus intubation. During cardiac arrest, if exhaled CO 2 is not detected, confirm tube position with direct laryngoscopy (Class IIa; LOE 5 46–49 ;6 50 ) because the absence of CO 2 may be a reflection of low pulmonary blood flow. You may also detect a low end-tidal CO 2 in the following circumstances: ● If the detector is contaminated with gastric contents or acidic drugs (eg, endotracheally administered epinephrine), you may see a constant color rather than breath-to-breath color change. ● An intravenous (IV) bolus of epinephrine may transiently reduce pulmonary blood flow and exhaled CO 2 below the limits of detection. 51 ● Severe airway obstruction (eg, status asthmaticus) and pulmonary edema may impair CO 2 elimination. 49,52–54 Esophageal Detector Devices The self-inflating bulb (esophageal detector device) may be considered to confirm endotracheal tube placement in chil- dren weighing H1102220 kg with a perfusing rhythm (Class IIb; LOE 2 55,56 ). There is insufficient data to make a recommen- dation for or against its use in children during cardiac arrest (Class Indeterminate). Transtracheal Catheter Ventilation Transtracheal catheter ventilation may be considered for support of oxygenation in the patient with severe airway obstruction if you cannot provide oxygen or ventilation any other way. Try transtracheal ventilation only if you are properly trained and have appropriate equipment. 57 Suction Devices A suction device with an adjustable suction regulator should be available. Use a maximum suction force of 80 to 120 mm Hg for suctioning the airway via an endotracheal tube. 58 You will need higher suction pressures and large-bore noncollapsible suction tubing as well as semirigid pharyngeal tips to suction the mouth and pharynx. Circulation Advanced cardiovascular life support techniques are useless without effective circulation, which is supported by good chest compressions during cardiac arrest. Good chest com- pressions require an adequate compression rate (100 com- Part 12: Pediatric Advanced Life Support IV-169 pressions per minute), an adequate compression depth (about one third to one half of the anterior-posterior diameter), full recoil of the chest after each compression, and minimal interruptions in compressions. Unfortunately, good compres- sions are not always performed for many reasons, 14 including rescuer fatigue and long or frequent interruptions to secure the airway, check the heart rhythm, and move the patient. Backboard A firm surface that extends from the shoulders to the waist and across the full width of the bed provides optimal support for effective chest compressions. In ambulances and mobile life support units, use a spine board. 59,60 CPR Techniques and Adjuncts There is insufficient data to make a recommendation for or against the use of mechanical devices to compress the sternum, active compression-decompression CPR, interposed abdominal compression CPR, pneumatic antishock garment during resuscitation from cardiac arrest, and open-chest direct heart compression (Class Indeterminate). For further infor- mation see Part 6: “CPR Techniques and Devices.” Extracorporeal Membrane Oxygenation Consider extracorporeal CPR for in-hospital cardiac arrest refractory to initial resuscitation attempts if the condition leading to cardiac arrest is reversible or amenable to heart transplantation, if excellent conventional CPR has been performed after no more than several minutes of no-flow cardiac arrest (arrest time without CPR), and if the institution is able to rapidly perform extracorporeal membrane oxygen- ation (Class IIb; LOE 5 61,62 ). Long-term survival is possible even after H1102250 minutes of CPR in selected patients. 61,62 Cardiovascular Monitoring Attach electrocardiographic (ECG) monitoring leads or defi- brillator pads as soon as possible and monitor blood pressure. If the patient has an indwelling arterial catheter, use the waveform to guide your technique in compressing the chest. A minor adjustment of your hand position or depth of compression can significantly improve the waveform. Vascular Access Vascular access is essential for administering medications and drawing blood samples. Venous access can be challeng- ing in infants and children during an emergency, whereas intraosseous (IO) access can be easily achieved. Limit the time you attempt venous access, 63 and if you cannot achieve reliable access quickly, establish IO access. In cardiac arrest immediate IO access is recommended if no other IV access is already in place. Intraosseous Access IO access is a rapid, safe, and effective route for the administration of medications and fluids, 64,65 and it may be used for obtaining an initial blood sample during resuscitation (Class IIa; LOE 3 65,66 ). You can safely administer epineph- rine, adenosine, fluids, blood products, 64,66 and catechol- amines. 67 Onset of action and drug levels achieved are comparable to venous administration. 68 You can also obtain blood specimens for type and crossmatch and for chemical and blood gas analysis even during cardiac arrest, 69 but acid-base analysis is inaccurate after sodium bicarbonate administration via the IO cannula. 70 Use manual pressure or an infusion pump to administer viscous drugs or rapid fluid boluses, 71,72 and follow each medication with a saline flush to promote entry into the central circulation. Venous Access A central intravenous line (IV) provides more secure long- term access, but central drug administration does not achieve higher drug levels or a substantially more rapid response than peripheral administration. 73 Endotracheal Drug Administration Any vascular access, IO or IV, is preferable, but if you cannot establish vascular access, you can give lipid-soluble drugs such as lidocaine, epinephrine, atropine, and naloxone (“LEAN”) 74,75 via the endotracheal tube, 76 although optimal endotracheal doses are unknown (Table 1). Flush with a minimum of 5 mL normal saline followed by 5 assisted manual ventilations. 77 If CPR is in progress, stop chest compressions briefly during administration of medications. Although naloxone and vasopressin may be given by the endotracheal route, there are no human studies to support a specific dose. Non–lipid-soluble drugs (eg, sodium bicarbon- ate and calcium) may injure the airway and should not be administered via the endotracheal route. Administration of resuscitation drugs into the trachea results in lower blood concentrations than the same dose given intravascularly. Furthermore, recent animal studies suggest that the lower epinephrine concentrations achieved when the drug is delivered by the endotracheal route may produce transient H9252-adrenergic effects. These effects can be detrimental, causing hypotension, lower coronary artery per- fusion pressure and flow, and reduced potential for return of spontaneous circulation. Thus, although endotracheal admin- istration of some resuscitation drugs is possible, IV or IO drug administration is preferred because it will provide a more predictable drug delivery and pharmacologic effect. Emergency Fluids and Medications Estimating Weight In the out-of-hospital setting a child’s weight is often un- known, and even experienced personnel may not be able to estimate it accurately. 78 Tapes with precalculated doses printed at various patient lengths are helpful and have been clinically validated. 35,78,79 Hospitalized patients should have weights and precalculated emergency drug doses recorded and readily available. Fluids Use an isotonic crystalloid solution (eg, lactated Ringer’s solution or normal saline) 80,81 to treat shock; there is no benefit in using colloid (eg, albumin) during initial resusci- tation. 82 Use bolus therapy with a glucose-containing solution to only treat documented hypoglycemia (Class IIb; LOE 2 83 ; 6 84 ). There is insufficient data to make a recommendation for IV-170 Circulation December 13, 2005 or against hypertonic saline for shock associated with head injuries or hypovolemia (Class Indeterminate). 85,86 Medications (See Table 1) Adenosine Adenosine causes a temporary atrioventricular (AV) nodal conduction block and interrupts reentry circuits that involve the AV node. It has a wide safety margin because of its short half-life. A higher dose may be required for peripheral administra- tion than central venous administration. 87,88 Based on exper- imental data 89 and a case report, 90 adenosine may also be given by IO route. Administer adenosine and follow with a rapid saline flush to promote flow toward the central circulation. Amiodarone Amiodarone slows AV conduction, prolongs the AV refrac- tory period and QT interval, and slows ventricular conduction (widens the QRS). Precautions Monitor blood pressure and administer as slowly as the patient’s clinical condition allows; it should be administered slowly to a patient with a pulse but may be given rapidly to a patient with cardiac arrest or ventricular fibrillation (VF). Amiodarone causes hypotension through its vasodilatory property. The severity of the hypotension is related to the infusion rate and is less common with the aqueous form of amiodarone. 91 Monitor the ECG because complications may include bradycardia, heart block, and torsades de pointes ventricular tachycardia (VT). Use extreme caution when administering with another drug causing QT prolongation, such as procain- amide. Consider obtaining expert consultation. Adverse ef- fects may be long lasting because the half-life is up to 40 days. 92 Atropine Atropine sulfate is a parasympatholytic drug that accelerates sinus or atrial pacemakers and increases AV conduction. TABLE 1. Medications for Pediatric Resuscitation and Arrhythmias Medication Dose Remarks Adenosine 0.1 mg/kg (maximum 6 mg) Repeat: 0.2 mg/kg (maximum 12 mg) Monitor ECG Rapid IV/IO bolus Amiodarone 5 mg/kg IV/IO; repeat up to 15 mg/kg Maximum: 300 mg Monitor ECG and blood pressure Adjust administration rate to urgency (give more slowly when perfusing rhythm present) Use caution when administering with other drugs that prolong QT (consider expert consultation) Atropine 0.02 mg/kg IV/IO 0.03 mg/kg ET* Repeat once if needed Higher doses may be used with organophosphate poisoning Minimum dose: 0.1 mg Maximum single dose: Child 0.5 mg Adolescent 1 mg Calcium chloride (10%) 20 mg/kg IV/IO (0.2 mL/kg) Slowly Adult dose: 5–10 mL Epinephrine 0.01 mg/kg (0.1 mL/kg 1:10 000) IV/IO 0.1 mg/kg (0.1 mL/kg 1:1000) ET* Maximum dose: 1 mg IV/IO; 10 mg ET May repeat q 3–5 min Glucose 0.5–1 g/kg IV/IO D 10 W: 5–10 mL/kg D 25 W: 2–4 mL/kg D 50 W: 1–2 mL/kg Lidocaine Bolus: 1 mg/kg IV/IO Maximum dose: 100 mg Infusion: 20–50 H9262g/kg per minute ET*: 2–3 mg Magnesium sulfate 25–50 mg/kg IV/IO over 10–20 min; faster in torsades Maximum dose: 2g Naloxone H110215yorH1134920 kg: 0.1 mg/kg IV/IO/ET* H113505yorH1102220 kg: 2 mg IV/IO/ET* Use lower doses to reverse respiratory depression associated with therapeutic opioid use (1–15 H9262g/kg) Procainamide 15 mg/kg IV/IO over 30–60 min Adult dose: 20 mg/min IV infusion up to total maximum dose 17 mg/kg Monitor ECG and blood pressure Use caution when administering with other drugs that prolong QT (consider expert consultation) Sodium bicarbonate 1 mEq/kg per dose IV/IO slowly After adequate ventilation IV indicates intravenous; IO, intraosseous; and ET, via endotracheal tube. *Flush with 5 mL of normal saline and follow with 5 ventilations. Part 12: Pediatric Advanced Life Support IV-171 Precautions Small doses of atropine (H110210.1 mg) may produce paradoxical bradycardia. 93 Larger than recommended doses may be re- quired in special circumstances (eg, organophosphate poison- ing 94 or exposure to nerve gas agents). Calcium Routine administration of calcium does not improve outcome of cardiac arrest. 95 In critically ill children, calcium chloride may provide greater bioavailability than calcium gluconate. 96 Preferably administer calcium chloride via a central venous catheter because of the risk of sclerosis or infiltration with a peripheral venous line. Epinephrine The H9251-adrenergic-mediated vasoconstriction of epinephrine increases aortic diastolic pressure and thus coronary perfu- sion pressure, a critical determinant of successful resuscitation. 97,98 Precautions Administer all catecholamines through a secure line, prefer- ably into the central circulation; local ischemia, tissue injury, and ulceration may result from tissue infiltration. Do not mix catecholamines with sodium bicarbonate; alkaline solutions inactivate them. In patients with a perfusing rhythm, epinephrine causes tachycardia and may cause ventricular ectopy, tachyarrhythmias, hypertension, and vasoconstriction. 99 Glucose Infants have high glucose requirements and low glycogen stores and develop hypoglycemia when energy requirements rise. 100 Check blood glucose concentrations during and after arrest and treat hypoglycemia promptly (Class IIb; LOE 1 101 ; 7 [most extrapolated from neonates and adult ICU studies]). Lidocaine Lidocaine decreases automaticity and suppresses ventricular arrhythmias 102 but is not as effective as amiodarone for improving intermediate outcomes (ie, return of spontaneous circulation or survival to hospital admission) among adult patients with VF refractory to a shock and epinephrine. 103 Neither lidocaine nor amiodarone has been shown to improve survival to hospital discharge among patients with VF cardiac arrest. Precautions Lidocaine toxicity includes myocardial and circulatory de- pression, drowsiness, disorientation, muscle twitching, and seizures, especially in patients with poor cardiac output and hepatic or renal failure. 104,105 Magnesium There is insufficient evidence to recommend for or against the routine administration of magnesium during cardiac arrest (Class Indeterminate). 106–108 Magnesium is indicated for the treatment of documented hypomagnesemia or for torsades de pointes (polymorphic VT associated with long QT interval). Magnesium produces vasodilation and may cause hypoten- sion if administered rapidly. Procainamide Procainamide prolongs the refractory period of the atria and ventricles and depresses conduction velocity. Precautions There is little clinical data on using procainamide in infants and children. 109,110 Infuse procainamide very slowly while you monitor for hypotension, prolongation of the QT interval, and heart block. Stop the infusion if the QRS widens to H1102250% of baseline or if hypotension develops. Use extreme caution when administering with another drug causing QT prolongation, such as amiodarone. Consider obtaining expert consultation. Sodium Bicarbonate The routine administration of sodium bicarbonate has not been shown to improve outcome of resuscitation (Class Indeterminate). After you have provided effective ventilation and chest compressions and administered epinephrine, you may consider sodium bicarbonate for prolonged cardiac arrest (Class IIb; LOE 6). Sodium bicarbonate administration may be used for treatment of some toxidromes (see “Toxicologic Emergencies,” below) or special resuscitation situations. During cardiac arrest or severe shock, arterial blood gas analysis may not accurately reflect tissue and venous acidosis. 111,112 Precautions Excessive sodium bicarbonate may impair tissue oxygen delivery 113 ; cause hypokalemia, hypocalcemia, hypernatre- mia, and hyperosmolality 114,115 ; decrease the VF threshold 116 ; and impair cardiac function. Vasopressin There is limited experience with the use of vasopressin in pediatric patients, 117 and the results of its use in the treatment of adults with VF cardiac arrest have been inconsistent. 118–121 There is insufficient evidence to make a recommendation for or against the routine use of vasopressin during cardiac arrest (Class Indeterminate; LOE 5 117 ;6 121 ,7 118–120 [extrapolated from adult literature]). Pulseless Arrest In the text below, box numbers identify the corresponding box in the algorithm (Figure 1.) If a victim becomes unresponsive (Box 1), start CPR immediately (with supplementary oxygen if available) and send for a defibrillator (manual or automated external defi- brillator [AED]). Asystole and bradycardia with a wide QRS complex are most common in asphyxial cardiac arrest. 1,23 VF and pulseless electrical activity (PEA) are less common 122 and more likely to be observed in children with sudden arrest. If you are using an ECG monitor, determine the rhythm (Box 2); if you are using an AED, the device will tell you whether the rhythm is “shockable” (ie, VF or rapid VT), but it may not display the rhythm. “Shockable Rhythm”: VF/Pulseless VT (Box 3) VF occurs in 5% to 15% of all pediatric victims of out-of- hospital cardiac arrest 123–125 and is reported in up to 20% of IV-172 Circulation December 13, 2005 pediatric in-hospital arrests at some point during the resuscitation. The incidence increases with age. 123,125 De- fibrillation is the definitive treatment for VF (Class I) with an overall survival rate of 17% to 20%, 125–127 but in adults the probability of survival declines by 7% to 10% for each minute of arrest without CPR and defibrillation. 128 The decline in survival is more gradual when early CPR is provided. Defibrillators Defibrillators are either manual or automated (AED), with monophasic or biphasic waveforms. For further informa- tion see Part 5: “Electrical Therapies: Automated External Defibrillators, Defibrillation, Cardioversion, and Pacing.” Institutions that care for children at risk for arrhythmias and cardiac arrest (eg, hospitals, emergency departments) ideally should have defibrillators available that are capable of Figure 1. PALS Pulseless Arrest Algorithm. Part 12: Pediatric Advanced Life Support IV-173 energy adjustment that is appropriate for children. Many AED parameters are set automatically. When using a manual defibrillator, several elements should be considered, and they are highlighted below. Paddle Size Use the largest paddles or self-adhering electrodes 129–131 that will fit on the chest wall without touching (leave about 3 cm between the paddles). The best paddle size is ● Adult paddles (8 to 10 cm) for children H1102210 kg (more than approximately 1 year of age) ● Infant paddles for infants weighing H1102110 kg Interface The electrode–chest wall interface can be gel pads, electrode cream, paste, or self-adhesive monitoring-defibrillation pads. Do not use saline-soaked pads, ultrasound gel, bare paddles, or alcohol pads. Paddle Position Apply firm pressure on the paddles (manual) placed over the right side of the upper chest and the apex of the heart (to the left of the nipple over the left lower ribs). Alternatively place one electrode on the front of the chest just to the left of the sternum and the other over the upper back below the scapula. 132 Energy Dose The lowest energy dose for effective defibrillation and the upper limit for safe defibrillation in infants and children are not known. Energy doses H110224 J/kg (up to 9 J/kg) have effectively defibrillated children 133–135 and pediatric animal models 136 with negligible adverse effects. Based on data from adult studies 137,138 and pediatric animal models, 139–141 bipha- sic shocks appear to be at least as effective as monophasic shocks and less harmful. With a manual defibrillator (monophasic or biphasic), use a dose of 2 J/kg for the first attempt (Class IIa; LOE 5 142 ;6 136 ) and 4 J/kg for subsequent attempts (Class Indeterminate). AEDs Many AEDs can accurately detect VF in children of all ages 143–145 and differentiate shockable from nonshockable rhythms with a high degree of sensitivity and specifici- ty. 143,144 Since publication of the ECC Guidelines 2000, data has shown that AEDs can be safely and effectively used in children 1 to 8 years of age. 143–146 There is insufficient data to make a recommendation for or against using an AED in infants H110211 year of age (Class Indeterminate). 146 When using an AED for children about 1 to 8 years old, use a pediatric attenuator system, which decreases the delivered energy to a dose suitable for children (Class IIb; LOE 5 136 ;6 139,141 ). If an AED with a pediatric attenuating system is not available, use a standard AED, preferably one with sensitivity and specific- ity for pediatric shockable rhythms. It is recommended that systems and institutions caring for children and having AED programs should use AEDs with both a high specificity to recognize pediatric shockable rhythms and a pediatric atten- uating system. Defibrillation Sequence (Boxes 4, 5, 6, 7, 8) The following are important considerations: ● Attempt defibrillation immediately. The earlier you attempt defibrillation, the more likely the attempt will be successful. ● Provide CPR until the defibrillator is ready to deliver a shock, and resume CPR, beginning with chest compres- sions, immediately after shock delivery. Minimize inter- ruptions of chest compressions. In adults with a prolonged arrest 147,148 and animal models, 134,149 defibrillation is more likely to be successful after a period of effective chest compressions. Ideally, chest compressions should be inter- rupted only for ventilations (until an advanced airway is in place), rhythm check, and shock delivery. Rescuers should provide chest compressions after a rhythm check (when possible) while the defibrillator is charging. ● Give 1 shock (2 J/kg) as quickly as possible and immedi- ately resume CPR, beginning with chest compressions (Box 4). Biphasic defibrillators have a first shock success rate that exceeds 90%. 150 If 1 shock fails to eliminate VF, the incremental benefit of another shock is low, and resumption of CPR is likely to confer a greater value than another shock. CPR may provide some coronary perfusion with oxygen and substrate delivery, increasing the likeli- hood of defibrillation with a subsequent shock. It is important to minimize the time between any interruption in chest compressions and shock delivery and between shock delivery and resumption of postshock compressions. Check the rhythm (Box 5). Continue CPR for about 5 cycles (about 2 minutes). In in-hospital settings with continuous monitoring (eg, electrocardiographic, hemodynamic) in place, this sequence may be modified at the physician’s discretion (see Part 7.2: “Management of Cardiac Arrest”). ● Check the rhythm (Box 5). If a shockable rhythm persists, give 1 shock (4 J/kg), resume compressions immediately. Give a dose of epinephrine. The drug should be adminis- tered as soon as possible after the rhythm check. It is helpful if a third rescuer prepares the drug doses before the rhythm is checked so a drug can be administered as soon as possible after the rhythm is checked. A drug should be administered during the CPR that is performed while the defibrillator is charging or immediately after shock deliv- ery. However, the timing of drug administration is less important than the need to minimize interruptions in chest compressions. Use a standard dose of epinephrine for the first and subsequent doses (Class IIa; LOE 4). 151 There is no survival benefit from routine use of high-dose epinephrine, and it may be harmful, particularly in asphyxia (Class III; LOE 2, 4). 151 High-dose epinephrine may be considered in exceptional circumstances, such as H9252-blocker overdose (Class IIb). Give the standard dose of epinephrine about every 3 to 5 minutes during cardiac arrest. ● After 5 cycles (approximately 2 minutes) of CPR, check the rhythm (Box 7). If the rhythm continues to be “shock- able,” deliver a shock (4 J/kg), resume CPR (beginning with chest compressions) immediately, and give amio- darone (Class IIb; LOE 3, 7) 103, 152–154 or lidocaine if you IV-174 Circulation December 13, 2005 do not have amiodarone (Box 8) while CPR is provided. Continue CPR for 5 cycles (about 2 minutes) before again checking the rhythm and attempting to defibrillate if needed with 4 J/kg (you now have returned to Box 6). ● Once an advanced airway is in place, 2 rescuers no longer deliver cycles of CPR (ie, compressions interrupted by pauses for ventilation). Instead, the compressing rescuer should give continuous chest compressions at a rate of 100 per minute without pauses for ventilation. The rescuer delivering ventilation provides 8 to 10 breaths per minute. Two or more rescuers should rotate the compressor role approximately every 2 minutes to prevent compressor fatigue and deterioration in quality and rate of chest compressions. ● If you have a monitor or an AED with a rhythm display and there is an organized rhythm at any time, check for a pulse and proceed accordingly (Box 12). ● If defibrillation is successful but VF recurs, continue CPR while you give another bolus of amiodarone before you try to defibrillate with the previously successful shock dose (see Box 8). ● Search for and treat reversible causes (see green “During CPR” box). Torsades de Pointes This polymorphic VT is seen in patients with a long QT interval, which may be congenital or may result from toxicity with type I A antiarrhythmics (eg, procainamide, quinidine, and disopyramide) or type III antiarrhythmics (eg, sotalol and amiodarone), tricyclic antidepressants (see below), digitalis, or drug interactions. 155,156 These are examples of contributing factors listed in the green box in the algorithm. Treatment Regardless of the cause, treat torsades de pointes with a rapid (over several minutes) IV infusion of magnesium sulfate. “Nonshockable Rhythm”: Asystole/PEA (Box 9) The most common ECG findings in infants and children in cardiac arrest are asystole and PEA. PEA is organized electrical activity—most commonly slow, wide QRS com- plexes—without palpable pulses. Less frequently there is a sudden impairment of cardiac output with an initially normal rhythm but without pulses and with poor perfusion. This subcategory (formerly known as electromechanical dissocia- tion [EMD]) is more likely to be treatable. For asystole and PEA: ● Resume CPR and continue with as few interruptions in chest compressions as possible (Box 10). A second rescuer gives epinephrine while the first continues CPR. As with VF/pulseless VT, there is no survival benefit from routine high-dose epinephrine, and it may be harmful, particularly in asphyxia (Class III; LOE 2 151 ;6 99,157,158 ;7 159 ). Use a standard dose for the first and subsequent doses (Class IIa; LOE 4). 151 High-dose epinephrine may be considered in exceptional circumstances such as H9252-blocker overdose (Class IIb). ● Search for and treat reversible causes (see the green box). Bradycardia Box numbers in the text below refer to the corresponding boxes in the PALS Bradycardia Algorithm (Figure 2). The emergency treatment of bradycardia depends on its hemodynamic consequences. ● This algorithm applies to the care of the patient with bradycardia that is causing cardiorespiratory compromise (Box 1). If at any time the patient develops pulseless arrest, see the PALS Pulseless Arrest Algorithm. ● Support airway, breathing, and circulation as needed, administer oxygen, and attach a monitor/defibrillator (Box 2). ● Reassess the patient to determine if bradycardia is still causing cardiorespiratory symptoms despite support of adequate oxygenation and ventilation (Box 3). ● If pulses, perfusion, and respirations are normal, no emer- gency treatment is necessary. Monitor and proceed with evaluation (Box 5A). ● If heart rate is H1102160 beats per minute with poor perfusion despite effective ventilation with oxygen, start chest com- pressions (Box 6). ● Reevaluate the patient to determine if signs of hemody- namic compromise persist despite the support of adequate oxygenation and ventilation and compressions if indicated (Box 5). Verify that the support is adequate—eg, check airway and oxygen source and effectiveness of ventilation. ● Medications and pacing (Box 6) —Continue to support airway, ventilation, oxygenation (and provide compressions as needed) and give epineph- rine (Class IIa; LOE 7, 8). If bradycardia persists or responds only transiently, consider a continuous infusion of epinephrine or isoproterenol. —If bradycardia is due to vagal stimulation, give atropine (Class I) (Box 6). Emergency transcutaneous pacing may be lifesaving if the bradycardia is due to complete heart block or sinus node dysfunction unresponsive to venti- lation, oxygenation, chest compressions, and medica- tions, especially if it is associated with congenital or acquired heart disease (Class IIb; LOE 5, 7). 160 Pacing is not useful for asystole 160,161 or bradycardia due to post- arrest hypoxic/ischemic myocardial insult or respiratory failure. Tachycardia and Hemodynamic Instability The box numbers in the text below correspond to the numbered boxes in the Tachycardia Algorithm (Figure 3) If there are no palpable pulses, proceed with the PALS Pulseless Arrest Algorithm. If pulses are palpable and the patient has signs of hemodynamic compromise (poor perfu- sion, tachypnea, weak pulses), ensure that the airway is patent, assist ventilations if necessary, administer supplemen- tary oxygen, and attach an ECG monitor or defibrillator (Box 1). Assess QRS duration (Box 2): determine if the QRS duration is H113490.08 second (narrow-complex tachycardia) or H110220.08 second (wide-complex tachycardia). Narrow-Complex (<0.08 Second) Tachycardia Evaluation of a 12-lead ECG (Box 3) and the patient’s clinical presentation and history (Boxes 4 and 5) should help Part 12: Pediatric Advanced Life Support IV-175 you differentiate probable sinus tachycardia from probable supraventricular tachycardia (SVT). If the rhythm is sinus tachycardia, search for and treat reversible causes. Probable Supraventricular Tachycardia (Box 5) Monitor rhythm during therapy to evaluate effect. The choice of therapy depends on the patient’s degree of hemodynamic instability. ● Attempt vagal stimulation (Box 7) first unless the patient is very unstable and if it does not unduly delay chemical or electrical cardioversion (Class IIa; LOE 4, 5, 7, 8). In infants and young children, apply ice to the face without occluding the airway. 162,163 In older chil- dren, carotid sinus massage or Valsalva maneuvers are safe (Class IIb; LOE 5, 7). 164–166 One method of a Valsalva maneuver is to have the child blow through an obstructed straw. 165 Do not apply pressure to the eye because this can damage the retina. ● Chemical cardioversion with adenosine (Box 8) is very effective (Class IIa; LOE 2 87 ;3 88 ; 7 [extrapolation from adult studies]). If IV access is readily available administer adeno- sine using 2 syringes connected to a T-connector or stopcock; give adenosine rapidly with one syringe and immediately flush with H113505 mL of normal saline with the other. Figure 2. PALS Bradycardia Algorithm. IV-176 Circulation December 13, 2005 ● If the patient is very unstable or IV access is not readily available, provide electrical (synchronized) cardioversion (Box 8). Consider sedation if possible. Start with a dose of 0.5 to 1 J/kg. If unsuccessful, repeat using a dose of 2 J/kg. If a second shock is unsuccessful or the tachycardia recurs quickly, consider antiarrhythmic therapy (amiodarone or procainamide) before a third shock. ● Consider amiodarone or procainamide (Box 11) for SVT unresponsive to vagal maneuvers and adenosine (Class IIb; 5 153, 154 ;6 167–169 ; 7 [extrapolated from LOE 2 adult stud- ies] 103,152 ). Use extreme caution when administering more than one drug that causes QT prolongation (eg, amiodarone and procainamide). Consider obtaining expert consultation. Give an infusion of amiodarone or procainamide slowly (over several minutes to an hour), depending on the urgency, while you monitor the ECG and blood pressure. If there is no effect and there are no signs of toxicity, give additional doses (Table 1). ● Do not use verapamil in infants because it may cause refractory hypotension and cardiac arrest (Class III; LOE 5 170,171 ), and use with caution in children because it may cause hypotension and myocardial depression. 172 Wide-Complex (>0.08 Second) Tachycardia (Box 9) Wide-complex tachycardia with poor perfusion is probably ventric- ular in origin but may be supraventricular with aberrancy. 173 ● Treat with synchronized electrical cardioversion (0.5 J to 1 J/kg). If it does not delay cardioversion, try a dose of Figure 3. PALS Tachycardia Algorithm. Part 12: Pediatric Advanced Life Support IV-177 adenosine first to determine if the rhythm is SVT with aberrant conduction (Box 10). ● If a second shock (2 J/kg) is unsuccessful or if the tachycardia recurs quickly, consider antiarrhythmic therapy (amiodarone or procainamide) before a third shock (see above) (Box 11). Tachycardia With Hemodynamic Stability Because all arrhythmia therapies have the potential for serious adverse effects, consider consulting an expert in pediatric arrhythmias before treating children who are hemo- dynamically stable. ● For SVT, see above. ● For VT, give an infusion of amiodarone slowly (minutes to an hour depending on the urgency) (Class IIb; LOE 7 [extrapolated from adult studies]) while you monitor the ECG and blood pressure. If there is no effect and there are no signs of toxicity, give additional doses (Table 1). If amiodarone is not available, consider giving procainamide slowly (over 30 to 60 minutes) while you monitor the ECG and blood pressure (Class IIb; LOE 5, 6, 7). Do not administer amiodarone and procainamide together without expert consultation. Special Resuscitation Situations Trauma Some aspects of trauma resuscitation require emphasis be- cause improperly performed resuscitation is a major cause of preventable pediatric death. 174 Common errors in pediatric trauma resuscitation include failure to open and maintain the airway, failure to provide appropriate fluid resuscitation, and failure to recognize and treat internal bleeding. Involve a qualified surgeon early, and if possible, transport a child with multisystem trauma to a trauma center with pediatric expertise. The following are special aspects of trauma resuscitation: ● When the mechanism of injury is compatible with spinal injury, restrict motion of the cervical spine and avoid traction or movement of the head and neck. Open and maintain the airway with a jaw thrust, and do not tilt the head. If you cannot open the airway with a jaw thrust, use head tilt–chin lift, because you must establish a patent airway. Because of the disproportionately large head size in infants and young children, optimal positioning may require re- cessing the occiput 60 or elevating the torso to avoid undesirable backboard-induced cervical flexion. 59,60 ● Do not overventilate (Class III; LOE 3 175 ; 5, 6) even in case of head injury. 176 Intentional brief hyperventilation may be used as a temporizing rescue therapy when you observe signs of impending brain herniation (eg, sudden rise in measured intracranial pressure, dilated pupil[s] not respon- sive to light, bradycardia, hypertension). ● Suspect thoracic injury in all thoracoabdominal trauma, even in the absence of external injuries. Tension pneumo- thorax, hemothorax, or pulmonary contusion may impair breathing. ● If the patient has maxillofacial trauma or if you suspect a basilar skull fracture, insert an orogastric rather than a nasogastric tube. 177 ● Treat signs of shock with a bolus of 20 mL/kg of an isotonic crystalloid (eg, normal saline or lactated Ringer’s solution) even if blood pressure is normal. Give additional boluses (20 mL/kg) if systemic perfusion fails to improve. If signs of shock persist after administration of 40 to 60 mL/kg of isotonic crystalloid, give 10 to 15 mL/kg of blood. Although type-specific crossmatched blood is pre- ferred, in an emergency use O-negative blood in females and O-positive or O-negative in males. If possible warm the blood before rapid infusion. 178,179 ● Consider intra-abdominal hemorrhage, tension pneumotho- rax, pericardial tamponade, spinal cord injury in infants and children, and intracranial hemorrhage in infants with signs of shock. 180,181 Children With Special Healthcare Needs Children with special healthcare needs 182–184 may require emergency care for their chronic conditions (eg, obstruction of a tracheostomy), failure of support technology (eg, venti- lator failure), progression of their underlying disease, or events unrelated to those special needs. 185 For additional information about CPR see Part 11: “Pediatric Basic Life Support.” Ventilation With a Tracheostomy or Stoma Parents, school nurses, and home healthcare providers should know how to assess patency of the airway, clear the airway, and perform CPR using the artificial airway in a child with a tracheostomy. Parents and providers should be able to provide ventilation via the tracheostomy tube and verify effectiveness by chest expansion. If you cannot ventilate after suctioning the tube, replace it. If a clean tube is unavailable, perform mouth-to- stoma or mask-to-stoma ventilations. If the upper airway is patent, you may be able to provide effective bag-mask ventilation through the nose and mouth while you or someone else occludes the tracheal stoma. Toxicologic Emergencies Overdose with cocaine, narcotics, tricyclic antidepressants, calcium channel blockers, and H9252-adrenergic blockers poses some unique resuscitation problems in addition to the usual resuscitative measures. Cocaine Acute coronary syndrome, manifested by chest pain and cardiac rhythm disturbances (including VT and VF), is the most frequent cocaine-related reason for hospitalization in adults. 186,187 Cocaine prolongs the action potential and QRS duration and impairs myocardial contractility. 188,189 Treatment ● Cool aggressively; hyperthermia is associated with an increase in toxicity. 190 ● For coronary vasospasm, consider nitroglycerin (Class IIa; LOE 5, 6), 191,192 a benzodiazepine, and phentolamine 193,194 (Class IIb; LOE 5, 6). IV-178 Circulation December 13, 2005 ● Do not give H9252-adrenergic blockers. 190 ● For ventricular arrhythmia, consider sodium bicarbonate (1 to 2 mEq/kg) 195,196 (Class IIb; LOE 5, 6, 7) in addition to standard treatments. ● To prevent arrhythmia secondary to myocardial infarction, consider a lidocaine bolus followed by a lidocaine infusion (Class IIb; LOE 5, 6). Tricyclic Antidepressants and Other Sodium Channel Blockers Toxic doses cause cardiovascular abnormalities, including intraventricular conduction delays, heart block, bradycardia, prolongation of the QT interval, ventricular arrhythmias (including torsades de pointes, VT, and VF), hypoten- sion, 189,197 seizures, and a depressed level of consciousness. Treatment ● Give 1 to 2 mEq/kg boluses of sodium bicarbonate until arterial pH isH110227.45, and then infuse 150 mEq NaHCO 3 per liter of D 5 W to maintain alkalosis. In severe intoxication, increase the pH to 7.50 to 7.55. 189,198 Do not administer Class I A (quinidine, procainamide), Class I C (flecainide, propafenone), or Class III (amiodarone and sotalol) antiar- rhythmics, which may exacerbate cardiac toxicity (Class III; LOE 6, 8). 198 ● For hypotension, give boluses (10 mL/kg each) of normal saline. If you need a vasopressor, epinephrine and norepi- nephrine have been shown to be more effective than dopamine in raising blood pressure. 199,200 ● Consider extracorporeal membrane oxygenation if high- dose vasopressors do not maintain blood pressure. 201,202 Calcium Channel Blockers Manifestations of toxicity include hypotension, ECG changes (prolongation of the QT interval, widening of the QRS, and right bundle branch block), arrhythmias (bradycardia, SVT, VT, torsades de pointes, and VF), 203 and altered mental status. Treatment ● Treat mild hypotension with small boluses (5 to 10 mL/kg) of normal saline because myocardial depression may limit the amount of fluid the patient can tolerate. ● The effectiveness of calcium administration is variable (Class IIb; LOE 7, 8). 203–207 Try giving 20 mg/kg (0.2 mL/kg) of 10% calcium chloride over 5 to 10 minutes; if there is a beneficial effect, give an infusion of 20 to 50 mg/kg per hour. Monitor ionized calcium concentration to prevent hypercalcemia. It is preferable to administer cal- cium chloride via a central venous catheter; use caution when infusing into a peripheral IV because of the risk for sclerosis or infiltration. ● For bradycardia and hypotension, consider a high-dose vasopressor such as norepinephrine or epinephrine (Class IIb; LOE 5). 206 ● There is insufficient data to recommend for or against an infusion of insulin and glucose 208–211 or sodium bicarbon- ate (Class Indeterminate). H9252-Adrenergic Blockers Toxic doses of H9252-adrenergic blockers cause bradycardia, heart block, and decreased cardiac contractility, and some (eg, propranolol and sotalol) may also prolong the QRS and the QT intervals. 211–214 Treatment ● High-dose epinephrine infusion may be effective 214,215 (Class Indeterminate; LOE 5, 6). ● Consider glucagon (Class IIb; LOE 5, 6). 211,214,216,217 In adolescents, infuse 5 to 10 mg of glucagon over several minutes followed by an IV infusion of 1 to 5 mg/h. If you are giving H110222 mg of glucagon, reconstitute it in sterile water (H110211 mg/mL) rather than the diluent supplied by the manufacturer. 217 ● Consider an infusion of glucose and insulin (Class Indeter- minate; LOE 6). 208 ● There is insufficient data to make a recommendation for or against using calcium (Class Indeterminate; LOE 5, 6). 204,218,219 Calcium may be considered if glucagon and catecholamine are ineffective (Class IIb; LOE 5, 6). Opioids Narcotics may cause hypoventilation, apnea, bradycardia, and hypotension. Treatment ● Ventilation is the initial treatment for severe respiratory depression from any cause (Class I). ● Naloxone reverses the respiratory depression of narcotic overdose (Class I; LOE: 1 220 ; LOE 2 221 ; LOE 3 222 ;5, 6 223,224 ), but in persons with long-term addictions or those with cardiovascular disease, naloxone may increase heart rate and blood pressure and cause acute pulmonary edema, cardiac arrhythmias (including asystole), and seizures. Ventilation before administration of naloxone appears to reduce these adverse effects. 225 Intramuscular administra- tion of naloxone may lower the risk. Postresuscitation Stabilization The goals of postresuscitation care are to preserve brain function, avoid secondary organ injury, diagnose and treat the cause of illness, and enable the patient to arrive at a pediatric tertiary-care facility in an optimal physiological state. Re- assess frequently because cardiorespiratory status may deteriorate. Respiratory System Continue supplementary oxygen until you confirm adequate blood oxygenation and oxygen delivery. Monitor by contin- uous pulse oximetry. Intubate and mechanically ventilate the patient if there is significant respiratory compromise (tachypnea, respiratory distress with agitation or decreased responsiveness, poor air exchange, cyanosis, hypoxemia). If the patient is already intubated, verify tube position, patency, and security. In the hospital setting, obtain arterial blood gases 10 to 15 minutes after establishing the initial ventilatory settings and make appropriate adjustments. Ideally correlate blood gases with capnographic end-tidal CO 2 concentration to enable noninva- sive monitoring of ventilation. Control pain and discomfort with analgesics (eg, fentanyl or morphine) and sedatives (eg, lorazepam, midazolam). In very agitated patients, neuromuscular blocking agents (eg, Part 12: Pediatric Advanced Life Support IV-179 vecuronium or pancuronium) with analgesia or sedation, or both, may improve ventilation and minimize the risk of tube displacement. Neuromuscular blockers, however, will mask seizures. Monitor exhaled CO 2 , especially during transport and diagnostic procedures. 226 Insert a gastric tube to relieve and help prevent gastric inflation. Cardiovascular System Continuously monitor heart rate, blood pressure (by direct arterial line if possible), and oxygen saturation. Repeat clinical evaluations at least every 5 minutes until the patient is stable. Monitor urine output with an indwelling catheter. Remove the IO access after you have alternate (preferably 2) secure venous lines. As a minimum, perform the following laboratory tests: central venous or arterial blood gas analysis and measurement of serum electrolytes, glucose, and calcium levels. A chest x-ray may help you evaluate endotracheal tube position, heart size, and pulmonary status. Drugs Used to Maintain Cardiac Output (Table 2) Myocardial dysfunction is common after cardiac arrest. 227,228 Systemic and pulmonary vascular resistance are increased except in some cases of septic shock. 229 Vasoactive agents may improve hemodynamics, but each drug and dose must be tailored to the patient (Class IIa; LOE 5, 6, 7) because clinical response is variable. Infuse all vasoactive drugs into a secure IV line. The potential adverse effects of catecholamines include local ischemia and ulceration, tachycardia, atrial and ventricular tachyarrhythmias, hypertension, and metabolic changes (hyperglycemia, increased lactate concentration, 230 and hypokalemia). Epinephrine Low-dose infusions (H110210.3 H9262g/kg per minute) generally pro- duce H9252-adrenergic action (potent inotropy and decreased systemic vascular resistance), and higher-dose infusions (H110220.3 H9262g/kg per minute) cause H9251-adrenergic vasoconstric- tion. 231 Because there is great interpatient variability, 232,233 titrate the drug to the desired effect. Epinephrine may be preferable to dopamine in patients (especially infants) with marked circulatory instability and decompensated shock. Dopamine Titrate dopamine to treat shock that is unresponsive to fluid and when systemic vascular resistance is low (Class IIb; LOE 5, 6, 7). 229,234 Typically a dose of 2 to 20 H9262g/kg per minute is used. Although low-dose dopamine infusion has been fre- quently recommended to maintain renal blood flow or im- prove renal function, more recent data has failed to show a beneficial effect from such therapy. At higher doses (H110225 H9262g/kg per minute), dopamine stimulates cardiac H9252-adrenergic receptors, but this effect may be reduced in infants and in chronic congestive heart failure. 231 Infusion rates H1102220 H9262g/kg per minute may result in excessive vasoconstriction. 231 Dobutamine Hydrochloride Dobutamine has a selective effect on H9252 1 - and H9252 2 -adrenergic receptors; it increases myocardial contractility and usually decreases peripheral vascular resistance. Titrate an infu- sion 232,235,236 to improve cardiac output and blood pressure, especially due to poor myocardial function. 236 Norepinephrine Norepinephrine is a potent inotropic and peripheral vasocon- stricting agent. Titrate an infusion to treat shock with low systemic vascular resistance (septic, anaphylactic, spinal, or vasodilatory) unresponsive to fluid. Sodium Nitroprusside Sodium nitroprusside increases cardiac output by decreasing vascular resistance (afterload). If hypotension is related to poor myocardial function, consider using a combination of sodium nitroprusside to reduce afterload and an inotrope to improve contractility. Inodilators Inodilators (inamrinone and milrinone) augment cardiac out- put with little effect on myocardial oxygen demand. Use an inodilator for treatment of myocardial dysfunction with in- creased systemic or pulmonary vascular resistance. 237–239 TABLE 2. Medications to Maintain Cardiac Output and for Postresuscitation Stabilization Medication Dose Range Comment Inamrinone 0.75–1 mg/kg IV/IO over 5 minutes; may repeat H11003 2; then: 2–20 H9262g/kg per minute Inodilator Dobutamine 2–20 H9262g/kg per minute IV/IO Inotrope; vasodilator Dopamine 2–20 H9262g/kg per minute IV/IO Inotrope; chronotrope; renal and splanchnic vasodilator in low doses; pressor in high doses Epinephrine 0.1–1 H9262g/kg per minute IV/IO Inotrope; chronotrope; vasodilator in low doses; pressor in higher doses Milrinone 50–75 H9262g/kg IV/IO over 10–60 min then 0.5–0.75 H9262g/kg per minute Inodilator Norepinephrine 0.1–2 H9262g/kg per minute Inotrope; vasopressor Sodium nitroprusside 1–8 H9262g/kg per minute Vasodilator; prepare only in D 5 W IV indicates intravenous; and IO, intraosseous. Alternative formula for calculating an infusion: Infusion rate (mL/h) H11005H20851weight (kg) H11003 dose (H9262g/kg/min) H11003 60 (min/h)H20852/concentration H9262g/mL). IV-180 Circulation December 13, 2005 Administration of fluids may be required because of the vasodilatory effects. Inodilators have a long half-life with a long delay in reaching a new steady-state hemodynamic effect after chang- ing the infusion rate (18 hours with inamrinone and 4.5 hours with milrinone). In case of toxicity, if you stop the infusion the adverse effects may persist for several hours. Neurologic System One goal of resuscitation is to preserve brain function. Prevent secondary neuronal injury by adhering to the follow- ing precautions: ● Do not provide routine hyperventilation. Hyperventilation has no benefit and may impair neurologic outcome, most likely by adversely affecting cardiac output and cerebral perfusion. 175 Intentional brief hyperventilation may be used as temporizing rescue therapy in response to signs of impending cerebral herniation (eg, sudden rise in measured intracranial pressure, dilated pupil[s] not responsive to light, bradycardia, hypertension). ● When patients remain comatose after resuscitation, con- sider cooling them to a temperature of 32°C to 34°C for 12 to 24 hours because cooling may aid brain recovery (Class IIb). Evidence in support of hypothermia is LOE 7 (extrap- olated from LOE 1 240 and LOE 2 241 studies in adults following resuscitation from VF sudden cardiac arrest and 2 LOE 2 neonatal studies 242,243 ). The ideal method and duration of cooling and rewarming are not known. Prevent shivering by providing sedation and, if needed, neuromus- cular blockade. Closely watch for signs of infection. Other complications of hypothermia include diminished cardiac output, arrhythmia, pancreatitis, coagulopathy, thrombocy- topenia, hypophosphatemia, and hypomagnesemia. Neuro- muscular blockade can mask seizures. ● Monitor temperature and treat fever aggressively with antipyretics and cooling devices because fever adversely influences recovery from ischemic brain injury (Class IIb; LOE 4, 5, 6). 244–248 ● Treat postischemic seizures aggressively; search for a correctable metabolic cause such as hypoglycemia or electrolyte imbalance. Renal System Decreased urine output (H110211 mL/kg per hour in infants and children or H1102130 mL/h in adolescents) may be caused by prerenal conditions (eg, dehydration, inadequate systemic perfusion), renal ischemic damage, or a combination of factors. Avoid nephrotoxic medications and adjust the dose of medications excreted by the kidneys until you have checked renal function. Interhospital Transport Ideally postresuscitation care should be provided by a trained team in a pediatric intensive care facility. Contact such a unit as early into the resuscitation attempt as possible and coor- dinate transportation with the receiving unit. 249 Transport team members should be trained and experienced in the care of critically ill and injured children 37,250 and supervised by a pediatric emergency medicine or pediatric critical care phy- sician. The mode of transport and composition of the team should be established for each system based on the care required by an individual patient. 251 Monitor exhaled CO 2 (qualitative colorimetric detector or capnography) during interhospital or intrahospital transport of intubated patients (Class IIa). Family Presence During Resuscitation Most family members would like to be present during resuscitation. 252–257 Parents and care providers of chronically ill children are often knowledgeable about and comfortable with medical equipment and emergency procedures. Family members with no medical background report that being at the side of a loved one and saying goodbye during the final moments of life is comforting 254,258 and helps in their adjust- ment, 252 and most would participate again. 254 Standardized psychological examinations suggest that, compared with those not present, family members who were present during attempted resuscitation have less anxiety and depression and more constructive grieving behavior. 257 Parents or family members often fail to ask, but healthcare providers should offer the opportunity whenever possible. 256,258,259 If the pres- ence of family members proves detrimental to the resuscita- tion, they should be gently asked to leave. Members of the resuscitation team must be sensitive to the presence of family members, and one person should be assigned to comfort, answer questions, and discuss the needs of the family. 260 Termination of Resuscitative Efforts Unfortunately there are no reliable predictors of outcome during resuscitation to guide when to terminate resuscitative efforts. Witnessed collapse, bystander CPR, and a short time interval from collapse to arrival of professionals improve the chances of a successful resuscitation. In the past, children who underwent prolonged resuscitation and absence of return of spontaneous circulation after 2 doses of epinephrine were considered unlikely to survive, 1,23,261 but intact survival after unusually prolonged in-hospital resuscitation has been docu- mented. 61,122,262–265 Prolonged efforts should be made for infants and children with recurring or refractory VF or VT, drug toxicity, or a primary hypothermic insult. For further discussion on the ethics of resuscitation, see Part 2: “Ethical Issues.” References 1. Young KD, Seidel JS. Pediatric cardiopulmonary resuscitation: a col- lective review. Ann Emerg Med. 1999;33:195–205. 2. Gorelick MH, Shaw KN, Murphy KO. Validity and reliability of clinical signs in the diagnosis of dehydration in children. Pediatrics. 1997; 99:E6. 3. Raju NV, Maisels MJ, Kring E, Schwarz-Warner L. Capillary refill time in the hands and feet of normal newborn infants. Clin Pediatr. 1999; 38:139–144. 4. Brown LH, Prasad NH, Whitley TW. Adverse lighting condition effects on the assessment of capillary refill. Am J Emerg Med. 1994;12:46–47. 5. Park C, Bahk JH, Ahn WS, Do SH, Lee KH. The laryngeal mask airway in infants and children. Can J Anaesth. 2001;48:413–417. 6. Bagshaw O. The size 1.5 laryngeal mask airway (LMA) in paediatric anaesthetic practice. Paediatr Anaesth. 2002;12:420–423. Part 12: Pediatric Advanced Life Support IV-181 7. Brown LH, Manring EA, Kornegay HB, Prasad NH. Can prehospital personnel detect hypoxemia without the aid of pulse oximeters? Am J Emerg Med. 1996;14:43–44. 8. Gausche M, Lewis RJ, Stratton SJ, Haynes BE, Gunter CS, Goodrich SM, Poore PD, McCollough MD, Henderson DP, Pratt FD, Seidel JS. Effect of out-of-hospital pediatric endotracheal intubation on survival and neurological outcome: a controlled clinical trial. JAMA. 2000;283: 783–790. 9. Cooper A, DiScala C, Foltin G, Tunik M, Markenson D, Welborn C. Prehospital endotracheal intubation for severe head injury in children: a reappraisal. Semin Pediatr Surg. 2001;10:3–6. 10. Stockinger ZT, McSwain NE Jr. Prehospital endotracheal intubation for trauma does not improve survival over bag-valve-mask ventilation. J Trauma. 2004;56:531–536. 11. Pitetti R, Glustein JZ, Bhende MS. Prehospital care and outcome of pediatric out-of-hospital cardiac arrest. Prehosp Emerg Care. 2002;6: 283–290. 12. Kern KB, Sanders AB, Raife J, Milander MM, Otto CW, Ewy GA. A study of chest compression rates during cardiopulmonary resuscitation in humans: the importance of rate-directed chest compressions. Arch Intern Med. 1992;152:145–149. 13. Aufderheide TP, Sigurdsson G, Pirrallo RG, Yannopoulos D, McKnite S, von Briesen C, Sparks CW, Conrad CJ, Provo TA, Lurie KG. Hyperventilation-induced hypotension during cardiopulmonary resusci- tation. Circulation. 2004;109:1960–1965. 14. Abella BS, Alvarado JP, Myklebust H, Edelson DP, Barry A, O’Hearn N, Vanden Hoek TL, Becker LB. Quality of cardiopulmonary resusci- tation during in-hospital cardiac arrest. JAMA. 2005;293:305–310. 15. Gausche-Hill M, Lewis RJ, Gunter CS, Henderson DP, Haynes BE, Stratton SJ. Design and implementation of a controlled trial of pediatric endotracheal intubation in the out-of-hospital setting. Ann Emerg Med. 2000;36:356–365. 16. Jesudian MC, Harrison RR, Keenan RL, Maull KI. Bag-valve-mask ventilation; two rescuers are better than one: preliminary report. Crit Care Med. 1985;13:122–123. 17. Davidovic L, LaCovey D, Pitetti R. Comparison of 1- vs 2-person bag-valve-mask techniques for manikin ventilation of infants and children. Ann Emerg Med. In press. 18. Berg MD, Idris AH, Berg RA. Severe ventilatory compromise due to gastric distention during pediatric cardiopulmonary resuscitation. Resus- citation. 1998;36:71–73. 19. Moynihan RJ, Brock-Utne JG, Archer JH, Feld LH, Kreitzman TR. The effect of cricoid pressure on preventing gastric insufflation in infants and children. Anesthesiology. 1993;78:652–656. 20. Salem MR, Wong AY, Mani M, Sellick BA. Efficacy of cricoid pressure in preventing gastric inflation during bag-mask ventilation in pediatric patients. Anesthesiology. 1974;40:96–98. 21. Sellick BA. Cricoid pressure to control regurgitation of stomach contents during induction of anaesthesia. Lancet. 1961;2:404–406. 22. Hartsilver EL, Vanner RG. Airway obstruction with cricoid pressure. Anaesthesia. 2000;55:208–211. 23. Sirbaugh PE, Pepe PE, Shook JE, Kimball KT, Goldman MJ, Ward MA, Mann DM. A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest [published correction appears in Ann Emerg Med. 1999;33:358]. Ann Emerg Med. 1999;33:174–184. 24. Brownstein DR, Quan L, Orr R, Wentz KR, Copass MK. Paramedic intubation training in a pediatric operating room. Am J Emerg Med. 1992;10:418–420. 25. Vilke GM, Steen PJ, Smith AM, Chan TC. Out-of-hospital pediatric intubation by paramedics: the San Diego experience. J Emerg Med. 2002;22:71–74. 26. Ma OJ, Atchley RB, Hatley T, Green M, Young J, Brady W. Intubation success rates improve for an air medical program after implementing the use of neuromuscular blocking agents. Am J Emerg Med. 1998;16: 125–127. 27. Sing RF, Rotondo MF, Zonies DH, Schwab CW, Kauder DR, Ross SE, Brathwaite CC. Rapid sequence induction for intubation by an aero- medical transport team: a critical analysis. Am J Emerg Med. 1998;16: 598–602. 28. Sagarin MJ, Chiang V, Sakles JC, Barton ED, Wolfe RE, Vissers RJ, Walls RM. Rapid sequence intubation for pediatric emergency airway management. Pediatr Emerg Care. 2002;18:417–423. 29. Deakers TW, Reynolds G, Stretton M, Newth CJ. Cuffed endotracheal tubes in pediatric intensive care. J Pediatr. 1994;125:57–62. 30. Khine HH, Corddry DH, Kettrick RG, Martin TM, McCloskey JJ, Rose JB, Theroux MC, Zagnoev M. Comparison of cuffed and uncuffed endotracheal tubes in young children during general anesthesia. Anes- thesiology. 1997;86:627–631; discussion 27A. 31. Newth CJ, Rachman B, Patel N, Hammer J. The use of cuffed versus uncuffed endotracheal tubes in pediatric intensive care. J Pediatr. 2004; 144:333–337. 32. Parwani V HI-H, Hsu B, Hoffman RJ. Experienced emergency phy- sicians cannot safely or accurately inflate endotracheal tube cuffs or estimate endotracheal tube cuff pressure using standard technique. Acad Emerg Med. 2004;11:490–491. 33. King BR, Baker MD, Braitman LE, Seidl-Friedman J, Schreiner MS. Endotracheal tube selection in children: a comparison of four methods. Ann Emerg Med. 1993;22:530–534. 34. van den Berg AA, Mphanza T. Choice of tracheal tube size for children: finger size or age-related formula? Anaesthesia. 1997;52:701–703. 35. Luten RC, Wears RL, Broselow J, Zaritsky A, Barnett TM, Lee T, Bailey A, Vally R, Brown R, Rosenthal B. Length-based endotracheal tube and emergency equipment in pediatrics. Ann Emerg Med. 1992;21: 900–904. 36. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. Ann Emerg Med. 2001;37: 32–37. 37. Beyer AJ III, Land G, Zaritsky A. Nonphysician transport of intubated pediatric patients: a system evaluation. Crit Care Med. 1992;20: 961–966. 38. Andersen KH, Schultz-Lebahn T. Oesophageal intubation can be unde- tected by auscultation of the chest. Acta Anaesthesiol Scand. 1994;38: 580–582. 39. Kelly JJ, Eynon CA, Kaplan JL, de Garavilla L, Dalsey WC. Use of tube condensation as an indicator of endotracheal tube placement. Ann Emerg Med. 1998;31:575–578. 40. Poirier MP, Gonzalez Del-Rey JA, McAneney CM, DiGiulio GA. Utility of monitoring capnography, pulse oximetry, and vital signs in the detection of airway mishaps: a hyperoxemic animal model. Am J Emerg Med. 1998;16:350–352. 41. Birmingham PK, Cheney FW, Ward RJ. Esophageal intubation: a review of detection techniques. Anesth Analg. 1986;65:886–891. 42. Donn SM, Kuhns LR. Mechanism of endotracheal tube movement with change of head position in the neonate. Pediatr Radiol. 1980;9:37–40. 43. Hartrey R, Kestin IG. Movement of oral and nasal tracheal tubes as a result of changes in head neck position. Anaesthesia. 1995;50:682–687. 44. Bhende MS, Thompson AE, Cook DR, Saville AL. Validity of a dis- posable end-tidal CO2 detector in verifying endotracheal tube placement in infants and children. Ann Emerg Med. 1992;21:142–145. 45. Campbell RC, Boyd CR, Shields RO, Odom JW, Corse KM. Evaluation of an end-tidal carbon dioxide detector in the aeromedical setting. J Air Med Transp. 1990;9:13–15. 46. Bhende MS, Thompson AE, Orr RA. Utility of an end-tidal carbon dioxide detector during stabilization and transport of critically ill children. Pediatrics. 1992;89(pt 1):1042–1044. 47. Bhende MS, Thompson AE. Evaluation of an end-tidal CO2 detector during pediatric cardiopulmonary resuscitation. Pediatrics. 1995;95: 395–399. 48. Cardoso MM, Banner MJ, Melker RJ, Bjoraker DG. Portable devices used to detect endotracheal intubation during emergency situations: a review. Crit Care Med. 1998;26:957–964. 49. Ornato JP, Shipley JB, Racht EM, Slovis CM, Wrenn KD, Pepe PE, Almeida SL, Ginger VF, Fotre TV. Multicenter study of a portable, hand-size, colorimetric end-tidal carbon dioxide detection device. Ann Emerg Med. 1992;21:518–523. 50. Bhende MS, Karasic DG, Karasic RB. End-tidal carbon dioxide changes during cardiopulmonary resuscitation after experimental asphyxial cardiac arrest. Am J Emerg Med. 1996;14:349–350. 51. Cantineau JP, Merckx P, Lambert Y, Sorkine M, Bertrand C, Duvaldestin P. Effect of epinephrine on end-tidal carbon dioxide pressure during prehospital cardiopulmonary resuscitation. Am J Emerg Med. 1994;12:267–270. 52. Ward KR, Yealy DM. End-tidal carbon dioxide monitoring in emergency medicine. Part 2: clinical applications. Acad Emerg Med. 1998;5:637–646. 53. Hand IL, Shepard EK, Krauss AN, Auld PA. Discrepancies between transcutaneous and end-tidal carbon dioxide monitoring in the critically ill neonate with respiratory distress syndrome. Crit Care Med. 1989;17: 556–559. IV-182 Circulation December 13, 2005 54. Tobias JD, Meyer DJ. Noninvasive monitoring of carbon dioxide during respiratory failure in toddlers and infants: end-tidal versus transcu- taneous carbon dioxide. Anesth Analg. 1997;85:55–58. 55. Sharieff GQ, Rodarte A, Wilton N, Bleyle D. The self-inflating bulb as an airway adjunct: is it reliable in children weighing less than 20 kilograms? Acad Emerg Med. 2003;10:303–308. 56. Sharieff GQ, Rodarte A, Wilton N, Silva PD, Bleyle D. The self- inflating bulb as an esophageal detector device in children weighing more than twenty kilograms: a comparison of two techniques. Ann Emerg Med. 2003;41:623–629. 57. Klain M, Keszler H, Brader E. High frequency jet ventilation in CPR. Crit Care Med. 1981;9:421–422. 58. Zander J, Hazinski MF. Pulmonary disorders: airway obstructions. In: Hazinski MF, ed. Nursing Care of the Critically Ill Child. St. Louis, Mo: Mosby-Year Book; 1992. 59. Nypaver M, Treloar D. Neutral cervical spine positioning in children. Ann Emerg Med. 1994;23:208–211. 60. Herzenberg JE, Hensinger RN, Dedrick DK, Phillips WA. Emergency transport and positioning of young children who have an injury of the cervical spine. The standard backboard may be hazardous. J Bone Joint Surg Am. 1989;71:15–22. 61. Duncan BW, Ibrahim AE, Hraska V, del Nido PJ, Laussen PC, Wessel DL, Mayer JE Jr, Bower LK, Jonas RA. Use of rapid-deployment extracorporeal membrane oxygenation for the resuscitation of pediatric patients with heart disease after cardiac arrest. J Thorac Cardiovasc Surg. 1998;116:305–311. 62. Morris MC, Wernovsky G, Nadkarni VM. Survival outcomes after extracorporeal cardiopulmonary resuscitation instituted during active chest compressions following refractory in-hospital pediatric cardiac arrest. Pediatr Crit Care Med. 2004;5:440–446. 63. Kanter RK, Zimmerman JJ, Strauss RH, Stoeckel KA. Pediatric emergency intravenous access. Evaluation of a protocol. Am J Dis Child. 1986;140:132–134. 64. Fiser DH. Intraosseous infusion. N Engl J Med. 1990;322:1579–1581. 65. Banerjee S, Singhi SC, Singh S, Singh M. The intraosseous route is a suitable alternative to intravenous route for fluid resuscitation in severely dehydrated children. Indian Pediatr. 1994;31:1511–1520. 66. Guy J, Haley K, Zuspan SJ. Use of intraosseous infusion in the pediatric trauma patient. J Pediatr Surg. 1993;28:158–161. 67. Berg RA. Emergency infusion of catecholamines into bone marrow. Am J Dis Child. 1984;138:810–811. 68. Andropoulos DB, Soifer SJ, Schreiber MD. Plasma epinephrine concen- trations after intraosseous and central venous injection during cardiopul- monary resuscitation in the lamb. J Pediatr. 1990;116:312–315. 69. Johnson L, Kissoon N, Fiallos M, Abdelmoneim T, Murphy S. Use of intraosseous blood to assess blood chemistries and hemoglobin during cardiopulmonary resuscitation with drug infusions. Crit Care Med. 1999;27:1147–1152. 70. Abdelmoneim T, Kissoon N, Johnson L, Fiallos M, Murphy S. Acid-base status of blood from intraosseous and mixed venous sites during prolonged cardiopulmonary resuscitation and drug infusions. Crit Care Med. 1999;27:1923–1928. 71. Orlowski JP, Porembka DT, Gallagher JM, Lockrem JD, VanLente F. Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. Am J Dis Child. 1990;144: 112–117. 72. Warren DW, Kissoon N, Sommerauer JF, Rieder MJ. Comparison of fluid infusion rates among peripheral intravenous and humerus, femur, malleolus, and tibial intraosseous sites in normovolemic and hypo- volemic piglets. Ann Emerg Med. 1993;22:183–186. 73. Fleisher G, Caputo G, Baskin M. Comparison of external jugular and peripheral venous administration of sodium bicarbonate in puppies. Crit Care Med. 1989;17:251–254. 74. Ward JTJ. Endotracheal drug therapy. Am J Emerg Med. 1983;1:71–82. 75. Johnston C. Endotracheal drug delivery. Pediatr Emerg Care. 1992;8: 94–97. 76. Efrati O, Ben-Abraham R, Barak A, Modan-Moses D, Augarten A, Manisterski Y, Barzilay Z, Paret G. Endobronchial adrenaline: should it be reconsidered? Dose response and haemodynamic effect in dogs. Resuscitation. 2003;59:117–122. 77. Jasani MS, Nadkarni VM, Finkelstein MS, Mandell GA, Salzman SK, Norman ME. Effects of different techniques of endotracheal epinephrine administration in pediatric porcine hypoxic-hypercarbic cardiopulmo- nary arrest. Crit Care Med. 1994;22:1174–1180. 78. Lubitz DS, Seidel JS, Chameides L, Luten RC, Zaritsky AL, Campbell FW. A rapid method for estimating weight and resuscitation drug dosages from length in the pediatric age group. Ann Emerg Med. 1988; 17:576–581. 79. Hofer CK, Ganter M, Tucci M, Klaghofer R, Zollinger A. How reliable is length-based determination of body weight and tracheal tube size in the paediatric age group? The Broselow tape reconsidered. Br J Anaesth. 2002;88:283–285. 80. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ. 1998;316:961–964. 81. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albu- min Reviewers. BMJ. 1998;317:235–240. 82. Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crys- talloids for fluid resuscitation in critically ill patients. In: The Cochrane Library. Oxford: England: Update Software. 2003. 83. Longstreth WT Jr, Copass MK, Dennis LK, Rauch-Matthews ME, Stark MS, Cobb LA. Intravenous glucose after out-of-hospital cardiopulmo- nary arrest: a community-based randomized trial. Neurology. 1993;43: 2534–2541. 84. Cherian L, Goodman JC, Robertson CS. Hyperglycemia increases brain injury caused by secondary ischemia after cortical impact injury in rats. Crit Care Med. 1997;25:1378–1383. 85. Simma B, Burger R, Falk M, Sacher P, Fanconi S. A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer’s solution versus hypertonic saline. Crit Care Med. 1998;26:1265–1270. 86. Bunn F, Roberts I, Tasker R, Akpa E. Hypertonic versus isotonic crystalloid for fluid resuscitation in critically ill patients. In: The Cochrane Library. Oxford, England: Update Software. 2003. 87. Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33: 185–191. 88. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, DiMarco JP. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol. 1988;61:336–340. 89. Getschman SJ, Dietrich AM, Franklin WH, Allen HD. Intraosseous adenosine: as effective as peripheral or central venous administration? Arch Pediatr Adolesc Med. 1994;148:616–619. 90. Friedman FD. Intraosseous adenosine for the termination of supraven- tricular tachycardia in an infant. Ann Emerg Med. 1996;28:356–358. 91. Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, Timar S, Molnar J. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90:853–859. 92. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmaco- kinetics. Am Heart J. 1983;106:840–847. 93. Dauchot P, Gravenstein JS. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther. 1971;12:274–280. 94. Zwiener RJ, Ginsburg CM. Organophosphate and carbamate poisoning in infants and children [published correction appears in Pediatrics. 1988;81:683]. Pediatrics. 1988;81:121–126. 95. Stueven HA, Thompson B, Aprahamian C, Tonsfeldt DJ, Kastenson EH. Lack of effectiveness of calcium chloride in refractory asystole. Ann Emerg Med. 1985;14:630–632. 96. Broner CW, Stidham GL, Westenkirchner DF, Watson DC. A pro- spective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. J Pediatr. 1990;117:986–989. 97. Niemann JT, Criley JM, Rosborough JP, Niskanen RA, Alferness C. Predictive indices of successful cardiac resuscitation after prolonged arrest and experimental cardiopulmonary resuscitation. Ann Emerg Med. 1985;14:521–528. 98. Sanders A, Ewy G, Taft T. Prognostic and therapeutic importance of the aortic diastolic pressure in resuscitation from cardiac arrest. Crit Care Med. 1984;12:871–873. 99. Berg RA, Otto CW, Kern KB, Sanders AB, Hilwig RW, Hansen KK, Ewy GA. High-dose epinephrine results in greater early mortality after resuscitation from prolonged cardiac arrest in pigs: a prospective, ran- domized study. Crit Care Med. 1994;22:282–290. 100. Losek JD. Hypoglycemia and the ABC’S (sugar) of pediatric resusci- tation. Ann Emerg Med. 2000;35:43–46. Part 12: Pediatric Advanced Life Support IV-183 101. Agus MSD, Jaksic T. Nutritional support of the critically ill child (review). Curr Opin Pediat. 2002;14:470–481. 102. Bigger JT Jr, Mandel WJ. Effect of lidocaine on the electrophysiological properties of ventricular muscle and purkinje fibers. J Clin Invest. 1970;49:63–77. 103. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884–890. 104. Wilson FC, Harpur J, Watson T, Morrow JI. Adult survivors of severe cerebral hypoxia–case series survey and comparative analysis. Neuro Rehabilitation. 2003;18:291–298. 105. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973;78:499–508. 106. Allegra J, Lavery R, Cody R, Birnbaum G, Brennan J, Hartman A, Horowitz M, Nashed A, Yablonski M. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. Resuscitation. 2001;49:245–249. 107. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg Med J. 2002;19:57–62. 108. Thel MC, Armstrong AL, McNulty SE, Califf RM, O’Connor CM. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet. 1997;350:1272–1276. 109. Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff- Parkinson-White and atrioventricular nodal reentry. Ann Pharmacother. 1997;31:1227–1243. 110. Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children, part 2: atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Ann Pharma- cother. 1997;31:1347–1359. 111. Weil MH, Rackow EC, Trevino R, Grundler W, Falk JL, Griffel MI. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med. 1986;315:153–156. 112. Steedman DJ, Robertson CE. Acid-base changes in arterial and central venous blood during cardiopulmonary resuscitation. Arch Emerg Med. 1992;9:169–176. 113. Wayne MA, Delbridge TR, Ornato JP, Swor RA, Blackwell T. Concepts and application of prehospital ventilation. Prehosp Emerg Care. 2001; 5:73–78. 114. Mattar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in the critically ill. II. Hyperosmolal states following cardiac arrest. Am J Med. 1974; 56:162–168. 115. Aufderheide TP, Martin DR, Olson DW, Aprahamian C, Woo JW, Hendley GE, Hargarten KM, Thompson B. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. Am J Emerg Med. 1992;10:4–7. 116. Bishop RL, Weisfeldt ML. Sodium bicarbonate administration during cardiac arrest. Effect on arterial pH PCO2, and osmolality. JAMA. 1976;235:506–509. 117. Mann K, Berg RA, Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. Resuscitation. 2002;52: 149–156. 118. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med. 2004;350:105–113. 119. Stiell IG, Hebert PC, Wells GA, Vandemheen KL, Tang AS, Higginson LA, Dreyer JF, Clement C, Battram E, Watpool I, Mason S, Klassen T, Weitzman BN. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet. 2001;358:105–109. 120. Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet. 1997;349:535–537. 121. Guyette FX, Guimond GE, Hostler D, Callaway CW. Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Resuscitation. 2004;63:277–282. 122. Reis AG, Nadkarni V, Perondi MB, Grisi S, Berg RA. A prospective investigation into the epidemiology of in-hospital pediatric cardiopul- monary resuscitation using the international Utstein reporting style. Pediatrics. 2002;109:200–209. 123. Appleton GO, Cummins RO, Larson MP, Graves JR. CPR and the single rescuer: at what age should you “call first” rather than “call fast”? Ann Emerg Med. 1995;25:492–494. 124. Hickey RW, Cohen DM, Strausbaugh S, Dietrich AM. Pediatric patients requiring CPR in the prehospital setting. Ann Emerg Med. 1995;25: 495–501. 125. Mogayzel C, Quan L, Graves JR, Tiedeman D, Fahrenbruch C, Herndon P. Out-of-hospital ventricular fibrillation in children and adolescents: causes and outcomes. Ann Emerg Med. 1995;25:484–491. 126. Herlitz J, Engdahl J, Svensson L, Young M, Angquist KA, Holmberg S. Characteristics and outcome among children suffering from out of hospital cardiac arrest in Sweden. Resuscitation. 2005;64:37–40. 127. Safranek DJ, Eisenberg MS, Larsen MP. The epidemiology of cardiac arrest in young adults. Ann Emerg Med. 1992;21:1102–1106. 128. Larsen MP, Eisenberg MS, Cummins RO, Hallstrom AP. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med. 1993;22:1652–1658. 129. Atkins DL, Sirna S, Kieso R, Charbonnier F, Kerber RE. Pediatric defibrillation: importance of paddle size in determining transthoracic impedance. Pediatrics. 1988;82:914–918. 130. Atkins DL, Kerber RE. Pediatric defibrillation: current flow is improved by using “adult” electrode paddles. Pediatrics. 1994;94:90–93. 131. Samson RA, Atkins DL, Kerber RE. Optimal size of self-adhesive preapplied electrode pads in pediatric defibrillation. Am J Cardiol. 1995;75:544–545. 132. Garcia LA, Kerber RE. Transthoracic defibrillation: does electrode adhesive pad position alter transthoracic impedance? Resuscitation. 1998;37:139–143. 133. Gurnett CA, Atkins DL. Successful use of a biphasic waveform automated external defibrillator in a high-risk child. Am J Cardiol. 2000;86:1051–1053. 134. Rossano JQ, Schiff L, Kenney MA, Atkins DL. Survival is not cor- related with defibrillation dosing in pediatric out-of-hospital ventricular fibrillation. Circulation. 2003;108:IV320–IV321. 135. Atkins D, Jorgenson D. Attenuated pediatric electrode pads for automated external defibrillator use in children. Resuscitation. 2005;66: 31–37. 136. Berg RA, Chapman FW, Berg MD, Hilwig RW, Banville I, Walker RG, Nova RC, Sherrill D, Kern KB. Attenuated adult biphasic shocks compared with weight-based monophasic shocks in a swine model of prolonged pediatric ventricular fibrillation. Resuscitation. 2004;61: 189–197. 137. Schneider T, Martens PR, Paschen H, Kuisma M, Wolcke B, Gliner BE, Russell JK, Weaver WD, Bossaert L, Chamberlain D. Multicenter, randomized, controlled trial of 150-J biphasic shocks compared with 200- to 360-J monophasic shocks in the resuscitation of out-of-hospital cardiac arrest victims. Circulation. 2000;102:1780–1787. 138. van Alem AP, Chapman FW, Lank P, Hart AA, Koster RW. A pro- spective, randomised and blinded comparison of first shock success of monophasic and biphasic waveforms in out-of-hospital cardiac arrest. Resuscitation. 2003;58:17–24. 139. Berg RA, Samson RA, Berg MD, Chapman FW, Hilwig RW, Banville I, Walker RG, Nova RC, Anavy N, Kern KB. Better outcome after pediatric defibrillation dosage than adult dosage in a swine model of pediatric ventricular fibrillation. J Am Coll Cardiol. 2005;45:786–789. 140. Clark CB, Zhang Y, Davies LR, Karlsson G, Kerber RE. Pediatric transthoracic defibrillation: biphasic versus monophasic waveforms in an experimental model. Resuscitation. 2001;51:159–163. 141. Tang W, Weil MH, Jorgenson D, Klouche K, Morgan C, Yu T, Sun S, Snyder D. Fixed-energy biphasic waveform defibrillation in a pediatric model of cardiac arrest and resuscitation. Crit Care Med. 2002;30: 2736–2741. 142. Gutgesell HP, Tacker WA, Geddes LA, Davis S, Lie JT, McNamara DG. Energy dose for ventricular defibrillation of children. Pediatrics. 1976;58:898–901. 143. Atkinson E, Mikysa B, Conway JA, Parker M, Christian K, Deshpande J, Knilans TK, Smith J, Walker C, Stickney RE, Hampton DR, Hazinski MF. Specificity and sensitivity of automated external defibrillator rhythm analysis in infants and children. Ann Emerg Med. 2003;42: 185–196. 144. Cecchin F, Jorgenson DB, Berul CI, Perry JC, Zimmerman AA, Duncan BW, Lupinetti FM, Snyder D, Lyster TD, Rosenthal GL, Cross B, Atkins DL. Is arrhythmia detection by automatic external defibrillator accurate for children? Sensitivity and specificity of an automatic external defibrillator algorithm in 696 pediatric arrhythmias. Circu- lation. 2001;103:2483–2488. IV-184 Circulation December 13, 2005 145. Atkins DL, Hartley LL, York DK. Accurate recognition and effective treatment of ventricular fibrillation by automated external defibrillators in adolescents. Pediatrics. 1998;101(pt 1):393–397. 146. Samson RA, Berg RA, Bingham R, Biarent D, Coovadia A, Hazinski MF, Hickey RW, Nadkarni V, Nichol G, Tibballs J, Reis AG, Tse S, Zideman D, Potts J, Uzark K, Atkins D. Use of automated external defibrillators for children: an update: an advisory statement from the pediatric advanced life support task force, International Liaison Com- mittee on Resuscitation. Circulation. 2003;107:3250–3255. 147. Cobb LA, Fahrenbruch CE, Walsh TR, Copass MK, Olsufka M, Breskin M, Hallstrom AP. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. 1999;281:1182–1188. 148. Wik L, Hansen TB, Fylling F, Steen T, Vaagenes P, Auestad BH, Steen PA. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. JAMA. 2003;289:1389–1395. 149. Yakaitis RW, Ewy GA, Otto CW, Taren DL, Moon TE. Influence of time and therapy on ventricular defibrillation in dogs. Crit Care Med. 1980;8:157–163. 150. Martens PR, Russell JK, Wolcke B, Paschen H, Kuisma M, Gliner BE, Weaver WD, Bossaert L, Chamberlain D, Schneider T. Optimal Response to Cardiac Arrest study: defibrillation waveform effects. Resuscitation. 2001;49:233–243. 151. Perondi M, Reis A, Paiva E, Nadkarni V, Berg RA. A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. N Engl J Med. 2004;350:1722–1730. 152. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871–878. 153. Perry JC, Fenrich AL, Hulse JE, Triedman JK, Friedman RA, Lamberti JJ. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol. 1996;27:1246–1250. 154. Perry JC, Knilans TK, Marlow D, Denfield SW, Fenrich AL, Friedman RA. Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults. J Am Coll Cardiol. 1993;22:95–98. 155. van Haarst AD, van’t Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 1998;64:542–546. 156. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096. 157. Berg RA, Otto CW, Kern KB, Hilwig RW, Sanders AB, Henry CP, Ewy GA. A randomized, blinded trial of high-dose epinephrine versus standard-dose epinephrine in a swine model of pediatric asphyxial cardiac arrest. Crit Care Med. 1996;24:1695–1700. 158. Tang W, Weil MH, Sun S, Noc M, Yang L, Gazmuri RJ. Epinephrine increases the severity of postresuscitation myocardial dysfunction. Cir- culation. 1995;92:3089–3093. 159. Rivers EP, Wortsman J, Rady MY, Blake HC, McGeorge FT, Buderer NM. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest. 1994;106:1499–1507. 160. Beland MJ, Hesslein PS, Finlay CD, Faerron-Angel JE, Williams WG, Rowe RD. Noninvasive transcutaneous cardiac pacing in children. Pacing Clin Electrophysiol. 1987;10:1262–1270. 161. Quan L, Graves JR, Kinder DR, Horan S, Cummins RO. Transcutaneous cardiac pacing in the treatment of out-of-hospital pediatric cardiac arrests. Ann Emerg Med. 1992;21:905–909. 162. Sreeram N, Wren C. Supraventricular tachycardia in infants: response to initial treatment. Arch Dis Child. 1990;65:127–129. 163. Aydin M, Baysal K, Kucukoduk S, Cetinkaya F, Yaman S. Application of ice water to the face in initial treatment of supraventricular tachycardia. Turk J Pediatr. 1995;37:15–17. 164. Ornato JP, Hallagan LF, Reese WA, Clark RF, Tayal VS, Garnett AR, Gonzalez ER. Treatment of paroxysmal supraventricular tachycardia in the emergency department by clinical decision analysis [published cor- rection appears in Am J Emerg Med. 1990;8:85]. Am J Emerg Med. 1988;6:555–560. 165. Lim SH, Anantharaman V, Teo WS, Goh PP, Tan AT. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage. Ann Emerg Med. 1998;31:30–35. 166. Waxman MB, Wald RW, Sharma AD, Huerta F, Cameron DA. Vagal techniques for termination of paroxysmal supraventricular tachycardia. Am J Cardiol. 1980;46:655–664. 167. Gouin S, Ali S. A patient with chaotic atrial tachycardia. Pediatr Emerg Care. 2003;19:95–98. 168. Mandapati R, Byrum CJ, Kavey RE, Smith FC, Kveselis DA, Hannan WP, Brandt B III, Gaum WE. Procainamide for rate control of post- surgical junctional tachycardia. Pediatr Cardiol. 2000;21:123–128. 169. Wang JN, Wu JM, Tsai YC, Lin CS. Ectopic atrial tachycardia in children. J Formos Med Assoc. 2000;99:766–770. 170. Epstein ML, Kiel EA, Victorica BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pedi- atrics. 1985;75:737–740. 171. Kirk CR, Gibbs JL, Thomas R, Radley-Smith R, Qureshi SA. Cardio- vascular collapse after verapamil in supraventricular tachycardia. Arch Dis Child. 1987;62:1265–1266. 172. Rankin AC, Rae AP, Oldroyd KG, Cobbe SM. Verapamil or adenosine for the immediate treatment of supraventricular tachycardia. Q J Med. 1990;74:203–208. 173. Benson D Jr, Smith W, Dunnigan A, Sterba R, Gallagher J. Mechanisms of regular wide QRS tachycardia in infants and children. Am J Cardiol. 1982;49:1778–1788. 174. Dykes EH, Spence LJ, Young JG, Bohn DJ, Filler RM, Wesson DE. Preventable pediatric trauma deaths in a metropolitan region. J Pediatr Surg. 1989;24:107–110. 175. Buunke G, van der Hoeveen JG, Meinders AE. Cerebrovascular reac- tivity in comatose patients resuscitated from a cardiac arrest. Stroke. 1997;28:1569–1573. 176. Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer H, Young HF. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neu- rosurg. 1991;75:731–739. 177. Baskaya MK. Inadvertent intracranial placement of a nasogastric tube in patients with head injuries. Surg Neurol. 1999;52:426–427. 178. Rutledge R, Sheldon GF, Collins ML. Massive transfusion. Crit Care Clin. 1986;2:791–805. 179. Niven MJ, Zohar M, Shimoni Z, Glick J. Symptomatic hypocalcemia precipitated by small-volume blood transfusion. Ann Emerg Med. 1998; 32:498–501. 180. Ramenofsky ML, Luterman A, Quindlen E, Riddick L, Curreri PW. Maximum survival in pediatric trauma: the ideal system. J Trauma. 1984;24:818–823. 181. Luterman A, Ramenofsky M, Berryman C, Talley MA, Curreri PW. Evaluation of prehospital emergency medical service (EMS): defining areas for improvement. J Trauma. 1983;23:702–707. 182. McPherson M, Arango P, Fox H, Lauver C, McManus M, Newacheck PW, Perrin JM, Shonkoff JP, Strickland B. A new definition of children with special health care needs. Pediatrics. 1998;102:137–140. 183. Newacheck PW, Strickland B, Shonkoff JP, Perrin JM, McPherson M, McManus M, Lauver C, Fox H, Arango P. An epidemiologic profile of children with special health care needs. Pediatrics. 1998;102:117–123. 184. Emergency preparedness for children with special health care needs. Committee on Pediatric Emergency Medicine. American Academy of Pediatrics. Pediatrics. 1999;104:e53. 185. Spaite DW, Conroy C, Tibbitts M, Karriker KJ, Seng M, Battaglia N, Criss EA, Valenzuela TD, Meislin HW. Use of emergency medical services by children with special health care needs. Prehosp Emerg Care. 2000;4:19–23. 186. Hollander JE, Hoffman RS, Gennis P, Fairweather P, DiSano MJ, Schumb DA, Feldman JA, Fish SS, Dyer S, Wax P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Asso- ciated Chest Pain (COCHPA) Study Group. Acad Emerg Med. 1994;1: 330–339. 187. Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med. 1990;88:325–331. 188. Bauman JL, Grawe JJ, Winecoff AP, Hariman RJ. Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations. J Clin Pharmacol. 1994;34:902–911. 189. Kolecki PF, Curry SC. Poisoning by sodium channel blocking agents. Crit Care Clin. 1997;13:829–848. 190. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897–903. Part 12: Pediatric Advanced Life Support IV-185 191. Brogan WCI, Lange RA, Kim AS, Moliterno DJ, Hillis LD. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. JAm Coll Cardiol. 1991;18:581–586. 192. Hollander JE, Hoffman RS, Gennis P, Fairweather P, DiSano MJ, Schumb DA, Feldman JA, Fish SS, Dyer S, Wax P, et al. Nitroglycerin in the treatment of cocaine associated chest pain–clinical safety and efficacy. J Toxicol Clin Toxicol. 1994;32:243–256. 193. Hoffman RS, Hollander JE. Evaluation of patients with chest pain after cocaine use. Crit Care Clin. 1997;13:809–828. 194. Lange RA, Cigarroa RG, Yancy CW Jr, Willard JE, Popma JJ, Sills MN, McBride W, Kim AS, Hillis LD. Cocaine-induced coronary-artery vaso- constriction. N Engl J Med. 1989;321:1557–1562. 195. Kerns W II, Garvey L, Owens J. Cocaine-induced wide complex dys- rhythmia. J Emerg Med. 1997;15:321–329. 196. Beckman KJ, Parker RB, Hariman RJ, Gallastegui JL, Javaid JI, Bauman JL. Hemodynamic and electrophysiological actions of cocaine: effects of sodium bicarbonate as an antidote in dogs. Circulation. 1991; 83:1799–1807. 197. Dziukas LJ, Vohra J. Tricyclic antidepressant poisoning. Med J Aust. 1991;154:344–350. 198. Liebelt EL. Targeted management strategies for cardiovascular toxicity from tricyclic antidepressant overdose: the pivotal role for alkalinization and sodium loading. Pediatr Emerg Care. 1998;14:293–298. 199. Teba L, Schiebel F, Dedhia HV, Lazzell VA. Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose. Am J Emerg Med. 1988;6:566–568. 200. Tran TP, Panacek EA, Rhee KJ, Foulke GE. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension. Acad Emerg Med. 1997;4:864–868. 201. Williams JM, Hollingshed MJ, Vasilakis A, Morales M, Prescott JE, Graeber GM. Extracorporeal circulation in the management of severe tricyclic antidepressant overdose. Am J Emerg Med. 1994;12:456–458. 202. Larkin GL, Graeber GM, Hollingshed MJ. Experimental amitriptyline poisoning: treatment of severe cardiovascular toxicity with cardiopul- monary bypass. Ann Emerg Med. 1994;23:480–486. 203. Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. 1993;22:196–200. 204. Henry M, Kay MM, Viccellio P. Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride. Am J Emerg Med. 1985;3:334–336. 205. Howarth DM, Dawson AH, Smith AJ, Buckley N, Whyte IM. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol. 1994;13:161–166. 206. Horowitz BZ, Rhee KJ. Massive verapamil ingestion: a report of two cases and a review of the literature. Am J Emerg Med. 1989;7:624–631. 207. Watling SM, Crain JL, Edwards TD, Stiller RA. Verapamil overdose: case report and review of the literature. Ann Pharmacother. 1992;26: 1373–1378. 208. Kerns W II, Schroeder D, Williams C, Tomaszewski C, Raymond R. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med. 1997;29:748–757. 209. Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993;267:744–750. 210. Yuan TH, Kerns WP II, Tomaszewski CA, Ford MD, Kline JA. Insulin- glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999;37:463–474. 211. Kerns W II, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. Emerg Med Clin North Am. 1994;12:365–390. 212. Lewis M, Kallenbach J, Germond C, Zaltzman M, Muller F, Steyn J, Zwi S. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J. 1983;4:328–332. 213. Cruickshank JM, Neil-Dwyer G, Cameron MM, McAinsh J. Beta-adre- noreceptor-blocking agents and the blood-brain barrier. Clin Sci. 1980; 59(suppl 6):453s–455s. 214. Weinstein RS. Recognition and management of poisoning with beta- adrenergic blocking agents. Ann Emerg Med. 1984;13:1123–1131. 215. Avery GJD, Spotnitz HM, Rose EA, Malm JR, Hoffman BF. Pharma- cologic antagonism of beta-adrenergic blockade in dogs, I: hemodynam- ic effects of isoproterenol, dopamine, and epinephrine in acute propran- olol administration. J Thorac Cardiovasc Surg. 1979;77:267–276. 216. Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Crit Care Med. 1988; 16:246–251. 217. Mofenson HC, Caraccio TR, Laudano J. Glucagon for propranolol overdose. JAMA. 1986;255:2025–2026. 218. Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Ann Emerg Med. 1996;28:1–6. 219. Haddad LM. Resuscitation after nifedipine overdose exclusively with intravenous calcium chloride. Am J Emerg Med. 1996;14:602–603. 220. Mc Guire W, Fowlie PW. Naloxone for narcotic exposed newborn infants: systematic review. Arch Dis Child Fetal Neonatal Ed. 2003;88: F308–F311. 221. Chernick V, Manfreda J, DeBooy V, Davi M, Rigalto H, Seshia M. Clinical trial of naloxone in birth asphyxia. J Pediatr. 1988;113: 519–525. 222. Fischer CG, Cook DR. The respiratory and narcotic antagonistic effects of naloxone in infants. Anesth Analg. 1974;53:849–852. 223. Kattwinkel J, Niermeyer S, Nadkarni V, Tibballs J, Phillips B, Zideman D, Van Reempts P, Osmond M. An advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Middle East J Anesthesiol. 2001;16:315–351. 224. American Academy of Pediatrics Committee on Drugs. Naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children. Pediatrics. 1990;86: 484–485. 225. Mills CA, Flacke JW, Flacke WE, Bloor BC, Liu MD. Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J Anaesth. 1990;37:238–244. 226. Tobias JD, Lynch A, Garrett J. Alterations of end-tidal carbon dioxide during the intrahospital transport of children. Pediatr Emerg Care. 1996;12:249–251. 227. Kern KB, Hilwig RW, Berg RA, Rhee KH, Sanders AB, Otto CW, Ewy GA. Postresuscitation left ventricular systolic and diastolic dysfunction: treatment with dobutamine. Circulation. 1997;95:2610–2613. 228. Meyer RJ, Kern KB, Berg RA, Hilwig RW, Ewy GA. Post-resuscitation right ventricular dysfunction: delineation and treatment with dobuta- mine. Resuscitation. 2002;55:187–191. 229. Ceneviva G, Paschall JA, Maffei F, Carcillo JA. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics. 1998;102:e19. 230. Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A. Comparison of norepinephrine and dobutamine to epineph- rine for hemodynamics, lactate metabolism, and gastric tonometric vari- ables in septic shock: a prospective, randomized study. Intensive Care Med. 1997;23:282–287. 231. Zaritsky AL. Catecholamines, inotropic medications, and vasopressor agents. In: Chernow B, ed. The Pharmacologic Approach to the Crit- ically Ill Patient. 3rd ed. Baltimore, Md: Williams & Wilkins; 1994: 387–404. 232. Berg RA, Padbury JF. Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. Crit Care Med. 1997;25:1247–1251. 233. Fisher DG, Schwartz PH, Davis AL. Pharmacokinetics of exogenous epinephrine in critically ill children. Crit Care Med. 1993;21:111–117. 234. Ushay HM, Notterman DA. Pharmacology of pediatric resuscitation. Pediatr Clin North Am. 1997;44:207–233. 235. Habib DM, Padbury JF, Anas NG, Perkin RM, Minegar C. Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit Care Med. 1992;20:601–608. 236. Martinez AM, Padbury JF, Thio S. Dobutamine pharmacokinetics and cardiovascular responses in critically ill neonates. Pediatrics. 1992;89: 47–51. 237. Barton P, Garcia J, Kouatli A, Kitchen L, Zorka A, Lindsay C, Lawless S, Giroir B. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock: a prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest. 1996;109:1302–1312. 238. Bailey JM, Miller BE, Lu W, Tosone SR, Kanter KR, Tam VK. The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. Anesthesiology. 1999;90:1012–1018. 239. Abdallah I, Shawky H. A randomised controlled trial comparing mil- rinone and epinephrine as inotropes in paediatric patients undergoing total correction of tetralogy of Fallot. Egyptian J Anaesthesia. 2003;19: 323–329. 240. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypo- thermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–556. IV-186 Circulation December 13, 2005 241. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–563. 242. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365: 663–670. 243. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353: 1574–1584. 244. Zeiner A, Holzer M, Sterz F, Schorkhuber W, Eisenburger P, Havel C, Kliegel A, Laggner AN. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. Arch Intern Med. 2001;161: 2007–2012. 245. Takasu A, Saitoh D, Kaneko N, Sakamoto T, Okada Y. Hyperthermia: is it an ominous sign after cardiac arrest? Resuscitation. 2001;49: 273–277. 246. Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke. 1998;29:529–534. 247. Hickey RW, Kochanek PM, Ferimer H, Alexander HL, Garman RH, Graham SH. Induced hyperthermia exacerbates neurologic neuronal histologic damage after asphyxial cardiac arrest in rats. Crit Care Med. 2003;31:531–535. 248. Shum-Tim D, Nagashima M, Shinoka T, Bucerius J, Nollert G, Lidov HG, du Plessis A, Laussen PC, Jonas RA. Postischemic hyperthermia exacerbates neurologic injury after deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 1998;116:780–792. 249. Henning R. Emergency transport of critically ill children: stabilisation before departure. Med J Aust. 1992;156:117–124. 250. Edge WE, Kanter RK, Weigle CG, Walsh RF. Reduction of morbidity in interhospital transport by specialized pediatric staff. Crit Care Med. 1994;22:1186–1191. 251. Guidelines for the transfer of critically ill patients. Guidelines Com- mittee of the American College of Critical Care Medicine; Society of Critical Care Medicine and American Association of Critical-Care Nurses Transfer Guidelines Task Force. Crit Care Med. 1993;21: 931–937. 252. Barratt F, Wallis DN. Relatives in the resuscitation room: their point of view. J Accid Emerg Med. 1998;15:109–111. 253. Boie ET, Moore GP, Brummett C, Nelson DR. Do parents want to be present during invasive procedures performed on their children in the emergency department? A survey of 400 parents. Ann Emerg Med. 1999;34:70–74. 254. Doyle CJ, Post H, Burney RE, Maino J, Keefe M, Rhee KJ. Family partici- pation during resuscitation: an option. Ann Emerg Med. 1987;16:673–675. 255. Hanson C, Strawser D. Family presence during cardiopulmonary resus- citation: Foote Hospital emergency department’s nine-year perspective. J Emerg Nurs. 1992;18:104–106. 256. Meyers TA, Eichhorn DJ, Guzzetta CE. Do families want to be present during CPR? A retrospective survey. J Emerg Nurs. 1998;24:400–405. 257. Robinson SM, Mackenzie-Ross S, Campbell Hewson GL, Egleston CV, Prevost AT. Psychological effect of witnessed resuscitation on bereaved relatives.[comment]. Lancet. 1998;352:614–617. 258. Boyd R. Witnessed resuscitation by relatives. Resuscitation. 2000;43:171–176. 259. Offord RJ. Should relatives of patients with cardiac arrest be invited to be present during cardiopulmonary resuscitation? Intensive Crit Care Nurs. 1998;14:288–293. 260. Eichhorn DJ, Meyers TA, Mitchell TG, Guzzetta CE. Opening the doors: family presence during resuscitation. J Cardiovasc Nurs. 1996; 10:59–70. 261. Zaritsky A, Nadkarni V, Getson P, Kuehl K. CPR in children. Ann Emerg Med. 1987;16:1107–1111. 262. Lopez-Herce J, Garcia C, Dominguez P, Carrillo A, Rodriguez-Nunez A, Calvo C, Delgado MA. Characteristics and outcome of cardiorespi- ratory arrest in children. Resuscitation. 2004;63:311–320. 263. Lopez-Herce J, Garcia C, Rodriguez-Nunez A, Dominguez P, Carrillo A, Calvo C, Delgado MA. Long-term outcome of paediatric cardiore- spiratory arrest in Spain. Resuscitation. 2005;64:79–85. 264. del Nido PJ, Dalton HJ, Thompson AE, Siewers RD. Extracorporeal membrane oxygenator rescue in children during cardiac arrest after cardiac surgery. Circulation. 1992;86(suppl):II-300–II-304. 265. Parra DA, Totapally BR, Zahn E, Jacobs J, Aldousany A, Burke RP, Chang AC. Outcome of cardiopulmonary resuscitation in a pediatric cardiac intensive care unit. Crit Care Med. 2000;28:3296–3300. Part 12: Pediatric Advanced Life Support IV-187